CN103242348B - Indoline diketopiperazines spirocyclic compound and its production and use - Google Patents
Indoline diketopiperazines spirocyclic compound and its production and use Download PDFInfo
- Publication number
- CN103242348B CN103242348B CN201310191384.5A CN201310191384A CN103242348B CN 103242348 B CN103242348 B CN 103242348B CN 201310191384 A CN201310191384 A CN 201310191384A CN 103242348 B CN103242348 B CN 103242348B
- Authority
- CN
- China
- Prior art keywords
- compound
- cells
- formula
- methanol
- cell
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 150000001875 compounds Chemical class 0.000 title claims abstract description 164
- 238000004519 manufacturing process Methods 0.000 title claims description 9
- OZNWGRBZZYWZJR-UHFFFAOYSA-N 2,3-dihydro-1H-indole piperazine-2,3-dione Chemical class O=C1NCCNC1=O.C1=CC=C2NCCC2=C1 OZNWGRBZZYWZJR-UHFFFAOYSA-N 0.000 title abstract description 6
- -1 indole quinoline diketopiperazine Chemical compound 0.000 claims abstract description 44
- 206010028980 Neoplasm Diseases 0.000 claims abstract description 36
- 210000004881 tumor cell Anatomy 0.000 claims abstract description 32
- 238000002360 preparation method Methods 0.000 claims abstract description 30
- 241001540751 Talaromyces ruber Species 0.000 claims abstract description 28
- 150000003839 salts Chemical class 0.000 claims abstract description 28
- 239000003814 drug Substances 0.000 claims abstract description 8
- 230000004663 cell proliferation Effects 0.000 claims abstract description 7
- 239000000126 substance Substances 0.000 claims abstract description 7
- 239000003795 chemical substances by application Substances 0.000 claims abstract description 5
- 102100021238 Dynamin-2 Human genes 0.000 claims abstract description 4
- 101000817607 Homo sapiens Dynamin-2 Proteins 0.000 claims abstract description 4
- 239000003112 inhibitor Substances 0.000 claims abstract description 4
- 229940121649 protein inhibitor Drugs 0.000 claims abstract description 4
- 239000012268 protein inhibitor Substances 0.000 claims abstract description 4
- 210000004027 cell Anatomy 0.000 claims description 183
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 claims description 114
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 claims description 107
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 claims description 54
- 238000010828 elution Methods 0.000 claims description 49
- 241000282414 Homo sapiens Species 0.000 claims description 42
- 229940125904 compound 1 Drugs 0.000 claims description 42
- WORJEOGGNQDSOE-UHFFFAOYSA-N chloroform;methanol Chemical compound OC.ClC(Cl)Cl WORJEOGGNQDSOE-UHFFFAOYSA-N 0.000 claims description 36
- 239000002904 solvent Substances 0.000 claims description 35
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 claims description 33
- 239000000741 silica gel Substances 0.000 claims description 33
- 229910002027 silica gel Inorganic materials 0.000 claims description 33
- 238000004809 thin layer chromatography Methods 0.000 claims description 32
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 31
- 229940125782 compound 2 Drugs 0.000 claims description 30
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 claims description 28
- 201000011510 cancer Diseases 0.000 claims description 27
- 238000004440 column chromatography Methods 0.000 claims description 22
- 238000000855 fermentation Methods 0.000 claims description 22
- 230000004151 fermentation Effects 0.000 claims description 22
- 239000007795 chemical reaction product Substances 0.000 claims description 21
- 239000000203 mixture Substances 0.000 claims description 21
- 239000002024 ethyl acetate extract Substances 0.000 claims description 20
- 238000004321 preservation Methods 0.000 claims description 19
- 239000000706 filtrate Substances 0.000 claims description 18
- 208000032839 leukemia Diseases 0.000 claims description 18
- 208000032791 BCR-ABL1 positive chronic myelogenous leukemia Diseases 0.000 claims description 17
- 206010006187 Breast cancer Diseases 0.000 claims description 17
- 208000026310 Breast neoplasm Diseases 0.000 claims description 17
- 208000010833 Chronic myeloid leukaemia Diseases 0.000 claims description 17
- 208000033761 Myelogenous Chronic BCR-ABL Positive Leukemia Diseases 0.000 claims description 17
- 206010017758 gastric cancer Diseases 0.000 claims description 17
- 230000002829 reductive effect Effects 0.000 claims description 17
- 238000000926 separation method Methods 0.000 claims description 17
- 208000036762 Acute promyelocytic leukaemia Diseases 0.000 claims description 16
- 208000033826 Promyelocytic Acute Leukemia Diseases 0.000 claims description 16
- 208000005718 Stomach Neoplasms Diseases 0.000 claims description 16
- 238000000034 method Methods 0.000 claims description 16
- 201000011549 stomach cancer Diseases 0.000 claims description 16
- 206010008342 Cervix carcinoma Diseases 0.000 claims description 15
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 claims description 15
- 125000000217 alkyl group Chemical group 0.000 claims description 15
- 201000010881 cervical cancer Diseases 0.000 claims description 15
- 239000000284 extract Substances 0.000 claims description 15
- 238000004128 high performance liquid chromatography Methods 0.000 claims description 15
- GBMDVOWEEQVZKZ-UHFFFAOYSA-N methanol;hydrate Chemical compound O.OC GBMDVOWEEQVZKZ-UHFFFAOYSA-N 0.000 claims description 15
- 125000003545 alkoxy group Chemical group 0.000 claims description 14
- 239000012046 mixed solvent Substances 0.000 claims description 14
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 claims description 14
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 claims description 13
- 230000002401 inhibitory effect Effects 0.000 claims description 13
- WFDIJRYMOXRFFG-UHFFFAOYSA-N Acetic anhydride Chemical compound CC(=O)OC(C)=O WFDIJRYMOXRFFG-UHFFFAOYSA-N 0.000 claims description 12
- WGLUMOCWFMKWIL-UHFFFAOYSA-N dichloromethane;methanol Chemical compound OC.ClCCl WGLUMOCWFMKWIL-UHFFFAOYSA-N 0.000 claims description 12
- 239000003480 eluent Substances 0.000 claims description 12
- 241000228143 Penicillium Species 0.000 claims description 11
- 206010009944 Colon cancer Diseases 0.000 claims description 9
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims description 9
- 125000004423 acyloxy group Chemical group 0.000 claims description 9
- 230000035755 proliferation Effects 0.000 claims description 9
- 208000029742 colonic neoplasm Diseases 0.000 claims description 8
- LNTHITQWFMADLM-UHFFFAOYSA-N gallic acid Chemical compound OC(=O)C1=CC(O)=C(O)C(O)=C1 LNTHITQWFMADLM-UHFFFAOYSA-N 0.000 claims description 8
- 201000007270 liver cancer Diseases 0.000 claims description 8
- 208000014018 liver neoplasm Diseases 0.000 claims description 8
- 201000005202 lung cancer Diseases 0.000 claims description 8
- 208000020816 lung neoplasm Diseases 0.000 claims description 8
- 239000003208 petroleum Substances 0.000 claims description 8
- 238000001914 filtration Methods 0.000 claims description 7
- 230000002147 killing effect Effects 0.000 claims description 7
- 238000004007 reversed phase HPLC Methods 0.000 claims description 7
- 229920006395 saturated elastomer Polymers 0.000 claims description 7
- 241001052560 Thallis Species 0.000 claims description 6
- 125000001231 benzoyloxy group Chemical group C(C1=CC=CC=C1)(=O)O* 0.000 claims description 6
- 238000001212 derivatisation Methods 0.000 claims description 6
- 210000000981 epithelium Anatomy 0.000 claims description 6
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 6
- 125000001424 substituent group Chemical group 0.000 claims description 6
- 230000006907 apoptotic process Effects 0.000 claims description 5
- 125000003118 aryl group Chemical group 0.000 claims description 5
- 238000006243 chemical reaction Methods 0.000 claims description 5
- 239000000460 chlorine Substances 0.000 claims description 5
- DENRZWYUOJLTMF-UHFFFAOYSA-N diethyl sulfate Chemical compound CCOS(=O)(=O)OCC DENRZWYUOJLTMF-UHFFFAOYSA-N 0.000 claims description 5
- 229940008406 diethyl sulfate Drugs 0.000 claims description 5
- 239000001257 hydrogen Substances 0.000 claims description 5
- 229910052739 hydrogen Inorganic materials 0.000 claims description 5
- 125000004435 hydrogen atom Chemical class [H]* 0.000 claims description 5
- 238000009629 microbiological culture Methods 0.000 claims description 5
- 238000000746 purification Methods 0.000 claims description 5
- 238000007670 refining Methods 0.000 claims description 5
- JXIKAEINJOQILP-UHFFFAOYSA-N 3,4,5-tris(phenylmethoxy)benzoyl chloride Chemical compound C=1C=CC=CC=1COC=1C(OCC=2C=CC=CC=2)=CC(C(=O)Cl)=CC=1OCC1=CC=CC=C1 JXIKAEINJOQILP-UHFFFAOYSA-N 0.000 claims description 4
- RKIDDEGICSMIJA-UHFFFAOYSA-N 4-chlorobenzoyl chloride Chemical compound ClC(=O)C1=CC=C(Cl)C=C1 RKIDDEGICSMIJA-UHFFFAOYSA-N 0.000 claims description 4
- CZKLEJHVLCMVQR-UHFFFAOYSA-N 4-fluorobenzoyl chloride Chemical compound FC1=CC=C(C(Cl)=O)C=C1 CZKLEJHVLCMVQR-UHFFFAOYSA-N 0.000 claims description 4
- SKDHHIUENRGTHK-UHFFFAOYSA-N 4-nitrobenzoyl chloride Chemical compound [O-][N+](=O)C1=CC=C(C(Cl)=O)C=C1 SKDHHIUENRGTHK-UHFFFAOYSA-N 0.000 claims description 4
- 239000007864 aqueous solution Substances 0.000 claims description 4
- PASDCCFISLVPSO-UHFFFAOYSA-N benzoyl chloride Chemical compound ClC(=O)C1=CC=CC=C1 PASDCCFISLVPSO-UHFFFAOYSA-N 0.000 claims description 4
- 238000006555 catalytic reaction Methods 0.000 claims description 4
- 235000004515 gallic acid Nutrition 0.000 claims description 4
- 229940074391 gallic acid Drugs 0.000 claims description 4
- 229910052736 halogen Inorganic materials 0.000 claims description 4
- 150000002367 halogens Chemical class 0.000 claims description 4
- 238000000338 in vitro Methods 0.000 claims description 4
- 230000001939 inductive effect Effects 0.000 claims description 4
- INQOMBQAUSQDDS-UHFFFAOYSA-N iodomethane Chemical compound IC INQOMBQAUSQDDS-UHFFFAOYSA-N 0.000 claims description 4
- 230000008569 process Effects 0.000 claims description 4
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 claims description 3
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 claims description 3
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 claims description 3
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 claims description 3
- 125000000051 benzyloxy group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])O* 0.000 claims description 3
- 239000003139 biocide Substances 0.000 claims description 3
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 claims description 3
- 229910052794 bromium Inorganic materials 0.000 claims description 3
- 230000022534 cell killing Effects 0.000 claims description 3
- 229910052801 chlorine Inorganic materials 0.000 claims description 3
- 239000003937 drug carrier Substances 0.000 claims description 3
- 239000011737 fluorine Substances 0.000 claims description 3
- 229910052731 fluorine Inorganic materials 0.000 claims description 3
- 239000011630 iodine Substances 0.000 claims description 3
- 229910052740 iodine Inorganic materials 0.000 claims description 3
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims description 3
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 3
- 230000000118 anti-neoplastic effect Effects 0.000 claims description 2
- 229940034982 antineoplastic agent Drugs 0.000 claims description 2
- 208000019065 cervical carcinoma Diseases 0.000 claims description 2
- 238000002386 leaching Methods 0.000 claims description 2
- 201000009030 Carcinoma Diseases 0.000 claims 2
- 208000010667 Carcinoma of liver and intrahepatic biliary tract Diseases 0.000 claims 1
- 206010073069 Hepatic cancer Diseases 0.000 claims 1
- 201000008275 breast carcinoma Diseases 0.000 claims 1
- 208000010749 gastric carcinoma Diseases 0.000 claims 1
- 206010073071 hepatocellular carcinoma Diseases 0.000 claims 1
- 201000002250 liver carcinoma Diseases 0.000 claims 1
- 201000005296 lung carcinoma Diseases 0.000 claims 1
- 201000000498 stomach carcinoma Diseases 0.000 claims 1
- 230000001225 therapeutic effect Effects 0.000 claims 1
- 230000000259 anti-tumor effect Effects 0.000 abstract description 22
- 238000002474 experimental method Methods 0.000 abstract description 6
- IAYPIBMASNFSPL-UHFFFAOYSA-N Ethylene oxide Chemical group C1CO1 IAYPIBMASNFSPL-UHFFFAOYSA-N 0.000 abstract description 4
- RNXNMGPFJLESKN-UHFFFAOYSA-N 1-oxaspiro[4.5]decane Chemical compound C1CCOC21CCCCC2 RNXNMGPFJLESKN-UHFFFAOYSA-N 0.000 abstract description 3
- 239000002246 antineoplastic agent Substances 0.000 abstract description 3
- 229940041181 antineoplastic drug Drugs 0.000 abstract description 3
- 230000003013 cytotoxicity Effects 0.000 abstract description 3
- 231100000135 cytotoxicity Toxicity 0.000 abstract description 3
- 239000000411 inducer Substances 0.000 abstract description 3
- 238000009833 condensation Methods 0.000 abstract description 2
- 230000005494 condensation Effects 0.000 abstract description 2
- 238000005516 engineering process Methods 0.000 abstract description 2
- 230000030833 cell death Effects 0.000 abstract 1
- 150000002500 ions Chemical class 0.000 description 57
- 239000000243 solution Substances 0.000 description 24
- 238000011161 development Methods 0.000 description 17
- 230000018109 developmental process Effects 0.000 description 17
- 230000005764 inhibitory process Effects 0.000 description 17
- 238000001514 detection method Methods 0.000 description 15
- 238000012360 testing method Methods 0.000 description 14
- 239000000047 product Substances 0.000 description 13
- 238000005917 acylation reaction Methods 0.000 description 12
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 10
- 239000007788 liquid Substances 0.000 description 10
- 239000000523 sample Substances 0.000 description 10
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical group [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 9
- 125000003302 alkenyloxy group Chemical group 0.000 description 9
- 229910052799 carbon Inorganic materials 0.000 description 9
- 230000000694 effects Effects 0.000 description 9
- 239000001963 growth medium Substances 0.000 description 9
- 230000000877 morphologic effect Effects 0.000 description 9
- 238000001228 spectrum Methods 0.000 description 9
- 239000000725 suspension Substances 0.000 description 9
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 8
- 108090000623 proteins and genes Proteins 0.000 description 8
- 239000011734 sodium Substances 0.000 description 8
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 8
- 125000003342 alkenyl group Chemical group 0.000 description 7
- 125000000304 alkynyl group Chemical group 0.000 description 7
- 125000005133 alkynyloxy group Chemical group 0.000 description 7
- 238000002156 mixing Methods 0.000 description 7
- 238000011160 research Methods 0.000 description 7
- 238000011282 treatment Methods 0.000 description 7
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 6
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 6
- 238000000605 extraction Methods 0.000 description 6
- 239000008103 glucose Substances 0.000 description 6
- 230000002906 microbiologic effect Effects 0.000 description 6
- 239000008194 pharmaceutical composition Substances 0.000 description 6
- 125000003003 spiro group Chemical group 0.000 description 6
- 239000007858 starting material Substances 0.000 description 6
- 229910002092 carbon dioxide Inorganic materials 0.000 description 5
- 239000000969 carrier Substances 0.000 description 5
- 238000011081 inoculation Methods 0.000 description 5
- 239000002609 medium Substances 0.000 description 5
- 230000001338 necrotic effect Effects 0.000 description 5
- 150000003254 radicals Chemical class 0.000 description 5
- 239000007787 solid Substances 0.000 description 5
- OWEGMIWEEQEYGQ-UHFFFAOYSA-N 100676-05-9 Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC2C(OC(O)C(O)C2O)CO)O1 OWEGMIWEEQEYGQ-UHFFFAOYSA-N 0.000 description 4
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical group N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 4
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 4
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 4
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 4
- GUBGYTABKSRVRQ-PICCSMPSSA-N Maltose Natural products O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@@H](CO)OC(O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-PICCSMPSSA-N 0.000 description 4
- 229930195725 Mannitol Natural products 0.000 description 4
- 238000005481 NMR spectroscopy Methods 0.000 description 4
- 240000007817 Olea europaea Species 0.000 description 4
- 239000001888 Peptone Substances 0.000 description 4
- 108010080698 Peptones Proteins 0.000 description 4
- 125000001931 aliphatic group Chemical group 0.000 description 4
- 238000004458 analytical method Methods 0.000 description 4
- 230000001640 apoptogenic effect Effects 0.000 description 4
- 229940041514 candida albicans extract Drugs 0.000 description 4
- 238000004587 chromatography analysis Methods 0.000 description 4
- 238000012258 culturing Methods 0.000 description 4
- 201000010099 disease Diseases 0.000 description 4
- 208000035475 disorder Diseases 0.000 description 4
- 235000013922 glutamic acid Nutrition 0.000 description 4
- 239000004220 glutamic acid Substances 0.000 description 4
- 230000001965 increasing effect Effects 0.000 description 4
- 238000003760 magnetic stirring Methods 0.000 description 4
- 230000014759 maintenance of location Effects 0.000 description 4
- 239000000594 mannitol Substances 0.000 description 4
- 235000010355 mannitol Nutrition 0.000 description 4
- 235000019319 peptone Nutrition 0.000 description 4
- 150000003413 spiro compounds Chemical class 0.000 description 4
- 239000003643 water by type Substances 0.000 description 4
- 239000012138 yeast extract Substances 0.000 description 4
- QDZOEBFLNHCSSF-PFFBOGFISA-N (2S)-2-[[(2R)-2-[[(2S)-1-[(2S)-6-amino-2-[[(2S)-1-[(2R)-2-amino-5-carbamimidamidopentanoyl]pyrrolidine-2-carbonyl]amino]hexanoyl]pyrrolidine-2-carbonyl]amino]-3-(1H-indol-3-yl)propanoyl]amino]-N-[(2R)-1-[[(2S)-1-[[(2R)-1-[[(2S)-1-[[(2S)-1-amino-4-methyl-1-oxopentan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-3-(1H-indol-3-yl)-1-oxopropan-2-yl]amino]-1-oxo-3-phenylpropan-2-yl]amino]-3-(1H-indol-3-yl)-1-oxopropan-2-yl]pentanediamide Chemical compound C([C@@H](C(=O)N[C@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(N)=O)NC(=O)[C@@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CCCCN)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](N)CCCNC(N)=N)C1=CC=CC=C1 QDZOEBFLNHCSSF-PFFBOGFISA-N 0.000 description 3
- 238000001644 13C nuclear magnetic resonance spectroscopy Methods 0.000 description 3
- WVDDGKGOMKODPV-UHFFFAOYSA-N Benzyl alcohol Chemical compound OCC1=CC=CC=C1 WVDDGKGOMKODPV-UHFFFAOYSA-N 0.000 description 3
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 3
- GHASVSINZRGABV-UHFFFAOYSA-N Fluorouracil Chemical compound FC1=CNC(=O)NC1=O GHASVSINZRGABV-UHFFFAOYSA-N 0.000 description 3
- 102000002002 Neurokinin-1 Receptors Human genes 0.000 description 3
- 108010040718 Neurokinin-1 Receptors Proteins 0.000 description 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- 102100024304 Protachykinin-1 Human genes 0.000 description 3
- 101800003906 Substance P Proteins 0.000 description 3
- 230000002159 abnormal effect Effects 0.000 description 3
- 125000002029 aromatic hydrocarbon group Chemical group 0.000 description 3
- 229960002949 fluorouracil Drugs 0.000 description 3
- 238000009472 formulation Methods 0.000 description 3
- 239000011521 glass Substances 0.000 description 3
- 238000011068 loading method Methods 0.000 description 3
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 description 3
- 229910052757 nitrogen Inorganic materials 0.000 description 3
- 230000003287 optical effect Effects 0.000 description 3
- AICOOMRHRUFYCM-ZRRPKQBOSA-N oxazine, 1 Chemical compound C([C@@H]1[C@H](C(C[C@]2(C)[C@@H]([C@H](C)N(C)C)[C@H](O)C[C@]21C)=O)CC1=CC2)C[C@H]1[C@@]1(C)[C@H]2N=C(C(C)C)OC1 AICOOMRHRUFYCM-ZRRPKQBOSA-N 0.000 description 3
- 239000001301 oxygen Substances 0.000 description 3
- 229910052760 oxygen Inorganic materials 0.000 description 3
- 235000018102 proteins Nutrition 0.000 description 3
- 102000004169 proteins and genes Human genes 0.000 description 3
- 230000000007 visual effect Effects 0.000 description 3
- RPABADYMEMUBEC-UHFFFAOYSA-N 1-oxaspiro[4.5]decan-8-one Chemical compound C1CC(=O)CCC11OCCC1 RPABADYMEMUBEC-UHFFFAOYSA-N 0.000 description 2
- IRABMPNBAAQRLL-UHFFFAOYSA-N 1h-indole;piperazine-2,3-dione Chemical class O=C1NCCNC1=O.C1=CC=C2NC=CC2=C1 IRABMPNBAAQRLL-UHFFFAOYSA-N 0.000 description 2
- 229920001817 Agar Polymers 0.000 description 2
- 241000894006 Bacteria Species 0.000 description 2
- 239000002028 Biomass Substances 0.000 description 2
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 2
- 108090000426 Caspase-1 Proteins 0.000 description 2
- 235000005979 Citrus limon Nutrition 0.000 description 2
- 244000131522 Citrus pyriformis Species 0.000 description 2
- 229920002261 Corn starch Polymers 0.000 description 2
- 241000283074 Equus asinus Species 0.000 description 2
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 2
- 229930193140 Neomycin Natural products 0.000 description 2
- 244000061775 Olea africana Species 0.000 description 2
- 235000002852 Olea africana Nutrition 0.000 description 2
- 239000012980 RPMI-1640 medium Substances 0.000 description 2
- 101100163901 Rattus norvegicus Asic2 gene Proteins 0.000 description 2
- 244000061456 Solanum tuberosum Species 0.000 description 2
- 235000002595 Solanum tuberosum Nutrition 0.000 description 2
- 230000021736 acetylation Effects 0.000 description 2
- 238000006640 acetylation reaction Methods 0.000 description 2
- 230000009471 action Effects 0.000 description 2
- 239000004480 active ingredient Substances 0.000 description 2
- 239000008272 agar Substances 0.000 description 2
- 239000007900 aqueous suspension Substances 0.000 description 2
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical group [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 2
- 239000002585 base Substances 0.000 description 2
- 239000011324 bead Substances 0.000 description 2
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 description 2
- 230000004071 biological effect Effects 0.000 description 2
- 230000009702 cancer cell proliferation Effects 0.000 description 2
- 239000003153 chemical reaction reagent Substances 0.000 description 2
- QSKWJTXWJJOJFP-UHFFFAOYSA-N chloroform;ethoxyethane Chemical compound ClC(Cl)Cl.CCOCC QSKWJTXWJJOJFP-UHFFFAOYSA-N 0.000 description 2
- 238000007796 conventional method Methods 0.000 description 2
- 239000008120 corn starch Substances 0.000 description 2
- 239000006071 cream Substances 0.000 description 2
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 2
- 210000000805 cytoplasm Anatomy 0.000 description 2
- 238000010790 dilution Methods 0.000 description 2
- 239000012895 dilution Substances 0.000 description 2
- 238000002072 distortionless enhancement with polarization transfer spectrum Methods 0.000 description 2
- 239000002552 dosage form Substances 0.000 description 2
- 239000002158 endotoxin Substances 0.000 description 2
- 238000006200 ethylation reaction Methods 0.000 description 2
- 239000012634 fragment Substances 0.000 description 2
- 238000010438 heat treatment Methods 0.000 description 2
- 150000002373 hemiacetals Chemical class 0.000 description 2
- 238000003919 heteronuclear multiple bond coherence Methods 0.000 description 2
- 238000003929 heteronuclear multiple quantum coherence Methods 0.000 description 2
- 238000007912 intraperitoneal administration Methods 0.000 description 2
- 238000001990 intravenous administration Methods 0.000 description 2
- 238000002955 isolation Methods 0.000 description 2
- 239000008101 lactose Substances 0.000 description 2
- 229920006008 lipopolysaccharide Polymers 0.000 description 2
- 239000006210 lotion Substances 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- 238000002844 melting Methods 0.000 description 2
- 230000008018 melting Effects 0.000 description 2
- 239000012528 membrane Substances 0.000 description 2
- XELZGAJCZANUQH-UHFFFAOYSA-N methyl 1-acetylthieno[3,2-c]pyrazole-5-carboxylate Chemical compound CC(=O)N1N=CC2=C1C=C(C(=O)OC)S2 XELZGAJCZANUQH-UHFFFAOYSA-N 0.000 description 2
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 2
- 244000005700 microbiome Species 0.000 description 2
- 239000002480 mineral oil Substances 0.000 description 2
- 235000010446 mineral oil Nutrition 0.000 description 2
- 230000004660 morphological change Effects 0.000 description 2
- 229960004927 neomycin Drugs 0.000 description 2
- 239000002674 ointment Substances 0.000 description 2
- 230000036961 partial effect Effects 0.000 description 2
- 235000019271 petrolatum Nutrition 0.000 description 2
- KHUXNRRPPZOJPT-UHFFFAOYSA-N phenoxy radical Chemical group O=C1C=C[CH]C=C1 KHUXNRRPPZOJPT-UHFFFAOYSA-N 0.000 description 2
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 2
- 239000013641 positive control Substances 0.000 description 2
- 239000000843 powder Substances 0.000 description 2
- 238000000425 proton nuclear magnetic resonance spectrum Methods 0.000 description 2
- 238000001953 recrystallisation Methods 0.000 description 2
- 238000001896 rotating frame Overhauser effect spectroscopy Methods 0.000 description 2
- 229930195734 saturated hydrocarbon Natural products 0.000 description 2
- 238000007790 scraping Methods 0.000 description 2
- 238000011218 seed culture Methods 0.000 description 2
- 239000008223 sterile water Substances 0.000 description 2
- UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 2
- 238000006467 substitution reaction Methods 0.000 description 2
- 239000000758 substrate Substances 0.000 description 2
- 239000003826 tablet Substances 0.000 description 2
- 238000010998 test method Methods 0.000 description 2
- 230000000699 topical effect Effects 0.000 description 2
- SWGJCIMEBVHMTA-UHFFFAOYSA-K trisodium;6-oxido-4-sulfo-5-[(4-sulfonatonaphthalen-1-yl)diazenyl]naphthalene-2-sulfonate Chemical compound [Na+].[Na+].[Na+].C1=CC=C2C(N=NC3=C4C(=CC(=CC4=CC=C3O)S([O-])(=O)=O)S([O-])(=O)=O)=CC=C(S([O-])(=O)=O)C2=C1 SWGJCIMEBVHMTA-UHFFFAOYSA-K 0.000 description 2
- 229930195735 unsaturated hydrocarbon Natural products 0.000 description 2
- 238000005303 weighing Methods 0.000 description 2
- HBENZIXOGRCSQN-VQWWACLZSA-N (1S,2S,6R,14R,15R,16R)-5-(cyclopropylmethyl)-16-[(2S)-2-hydroxy-3,3-dimethylpentan-2-yl]-15-methoxy-13-oxa-5-azahexacyclo[13.2.2.12,8.01,6.02,14.012,20]icosa-8(20),9,11-trien-11-ol Chemical compound N1([C@@H]2CC=3C4=C(C(=CC=3)O)O[C@H]3[C@@]5(OC)CC[C@@]2([C@@]43CC1)C[C@@H]5[C@](C)(O)C(C)(C)CC)CC1CC1 HBENZIXOGRCSQN-VQWWACLZSA-N 0.000 description 1
- PHDIJLFSKNMCMI-ITGJKDDRSA-N (3R,4S,5R,6R)-6-(hydroxymethyl)-4-(8-quinolin-6-yloxyoctoxy)oxane-2,3,5-triol Chemical compound OC[C@@H]1[C@H]([C@@H]([C@H](C(O1)O)O)OCCCCCCCCOC=1C=C2C=CC=NC2=CC=1)O PHDIJLFSKNMCMI-ITGJKDDRSA-N 0.000 description 1
- QKLXBIHSGMPUQS-FGZHOGPDSA-M (3r,5r)-7-[4-(4-fluorophenyl)-2,5-dimethyl-1-phenylpyrrol-3-yl]-3,5-dihydroxyheptanoate Chemical compound CC1=C(CC[C@@H](O)C[C@@H](O)CC([O-])=O)C(C=2C=CC(F)=CC=2)=C(C)N1C1=CC=CC=C1 QKLXBIHSGMPUQS-FGZHOGPDSA-M 0.000 description 1
- VPMIAOSOTOODMY-KJAPKAAFSA-N (4r)-6-[(e)-2-[6-tert-butyl-4-(4-fluorophenyl)-2-propan-2-ylpyridin-3-yl]ethenyl]-4-hydroxyoxan-2-one Chemical compound C([C@H](O)C1)C(=O)OC1/C=C/C=1C(C(C)C)=NC(C(C)(C)C)=CC=1C1=CC=C(F)C=C1 VPMIAOSOTOODMY-KJAPKAAFSA-N 0.000 description 1
- QRDAPCMJAOQZSU-KQQUZDAGSA-N (e)-3-[4-[(e)-3-(3-fluorophenyl)-3-oxoprop-1-enyl]-1-methylpyrrol-2-yl]-n-hydroxyprop-2-enamide Chemical compound C1=C(\C=C\C(=O)NO)N(C)C=C1\C=C\C(=O)C1=CC=CC(F)=C1 QRDAPCMJAOQZSU-KQQUZDAGSA-N 0.000 description 1
- JNPGUXGVLNJQSQ-BGGMYYEUSA-M (e,3r,5s)-7-[4-(4-fluorophenyl)-1,2-di(propan-2-yl)pyrrol-3-yl]-3,5-dihydroxyhept-6-enoate Chemical compound CC(C)N1C(C(C)C)=C(\C=C\[C@@H](O)C[C@@H](O)CC([O-])=O)C(C=2C=CC(F)=CC=2)=C1 JNPGUXGVLNJQSQ-BGGMYYEUSA-M 0.000 description 1
- VAVHMEQFYYBAPR-ITWZMISCSA-N (e,3r,5s)-7-[4-(4-fluorophenyl)-1-phenyl-2-propan-2-ylpyrrol-3-yl]-3,5-dihydroxyhept-6-enoic acid Chemical compound CC(C)C1=C(\C=C\[C@@H](O)C[C@@H](O)CC(O)=O)C(C=2C=CC(F)=CC=2)=CN1C1=CC=CC=C1 VAVHMEQFYYBAPR-ITWZMISCSA-N 0.000 description 1
- LDVVTQMJQSCDMK-UHFFFAOYSA-N 1,3-dihydroxypropan-2-yl formate Chemical compound OCC(CO)OC=O LDVVTQMJQSCDMK-UHFFFAOYSA-N 0.000 description 1
- LEACJMVNYZDSKR-UHFFFAOYSA-N 2-octyldodecan-1-ol Chemical compound CCCCCCCCCCC(CO)CCCCCCCC LEACJMVNYZDSKR-UHFFFAOYSA-N 0.000 description 1
- HIHOEGPXVVKJPP-JTQLQIEISA-N 5-fluoro-2-[[(1s)-1-(5-fluoropyridin-2-yl)ethyl]amino]-6-[(5-methyl-1h-pyrazol-3-yl)amino]pyridine-3-carbonitrile Chemical compound N([C@@H](C)C=1N=CC(F)=CC=1)C(C(=CC=1F)C#N)=NC=1NC=1C=C(C)NN=1 HIHOEGPXVVKJPP-JTQLQIEISA-N 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 1
- REDUQXCPUSNJOL-UHFFFAOYSA-N C(C1=CC=CC=C1)NC(CN(C(C1=CC=C(C=C1)C(C)C)=O)CC1=CC=C(C=C1)C(NO)=O)=O Chemical compound C(C1=CC=CC=C1)NC(CN(C(C1=CC=C(C=C1)C(C)C)=O)CC1=CC=C(C=C1)C(NO)=O)=O REDUQXCPUSNJOL-UHFFFAOYSA-N 0.000 description 1
- 0 CC(C[C@]1C[C@@](*)CCC1)=O Chemical compound CC(C[C@]1C[C@@](*)CCC1)=O 0.000 description 1
- 241000282693 Cercopithecidae Species 0.000 description 1
- CYSWUSAYJNCAKA-FYJFLYSWSA-N ClC1=C(C=CC=2N=C(SC=21)OCC)OC1=CC=C(C=N1)/C=C/[C@H](C)NC(C)=O Chemical compound ClC1=C(C=CC=2N=C(SC=21)OCC)OC1=CC=C(C=N1)/C=C/[C@H](C)NC(C)=O CYSWUSAYJNCAKA-FYJFLYSWSA-N 0.000 description 1
- OCUCCJIRFHNWBP-IYEMJOQQSA-L Copper gluconate Chemical class [Cu+2].OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O.OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O OCUCCJIRFHNWBP-IYEMJOQQSA-L 0.000 description 1
- 241000283073 Equus caballus Species 0.000 description 1
- 229930182566 Gentamicin Natural products 0.000 description 1
- CEAZRRDELHUEMR-URQXQFDESA-N Gentamicin Chemical compound O1[C@H](C(C)NC)CC[C@@H](N)[C@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](NC)[C@@](C)(O)CO2)O)[C@H](N)C[C@@H]1N CEAZRRDELHUEMR-URQXQFDESA-N 0.000 description 1
- 101000573199 Homo sapiens Protein PML Proteins 0.000 description 1
- CPELXLSAUQHCOX-UHFFFAOYSA-N Hydrogen bromide Chemical compound Br CPELXLSAUQHCOX-UHFFFAOYSA-N 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- SIKJAQJRHWYJAI-UHFFFAOYSA-N Indole Chemical compound C1=CC=C2NC=CC2=C1 SIKJAQJRHWYJAI-UHFFFAOYSA-N 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 241000533950 Leucojum Species 0.000 description 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 229930182555 Penicillin Natural products 0.000 description 1
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 1
- 241000009328 Perro Species 0.000 description 1
- 239000004264 Petrolatum Substances 0.000 description 1
- 229920003171 Poly (ethylene oxide) Polymers 0.000 description 1
- 229920001214 Polysorbate 60 Polymers 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- 241000589516 Pseudomonas Species 0.000 description 1
- 241000589517 Pseudomonas aeruginosa Species 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- HVUMOYIDDBPOLL-XWVZOOPGSA-N Sorbitan monostearate Chemical compound CCCCCCCCCCCCCCCCCC(=O)OC[C@@H](O)[C@H]1OC[C@H](O)[C@H]1O HVUMOYIDDBPOLL-XWVZOOPGSA-N 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 1
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical group [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 1
- FHKPLLOSJHHKNU-INIZCTEOSA-N [(3S)-3-[8-(1-ethyl-5-methylpyrazol-4-yl)-9-methylpurin-6-yl]oxypyrrolidin-1-yl]-(oxan-4-yl)methanone Chemical compound C(C)N1N=CC(=C1C)C=1N(C2=NC=NC(=C2N=1)O[C@@H]1CN(CC1)C(=O)C1CCOCC1)C FHKPLLOSJHHKNU-INIZCTEOSA-N 0.000 description 1
- YLEIFZAVNWDOBM-ZTNXSLBXSA-N ac1l9hc7 Chemical compound C([C@H]12)C[C@@H](C([C@@H](O)CC3)(C)C)[C@@]43C[C@@]14CC[C@@]1(C)[C@@]2(C)C[C@@H]2O[C@]3(O)[C@H](O)C(C)(C)O[C@@H]3[C@@H](C)[C@H]12 YLEIFZAVNWDOBM-ZTNXSLBXSA-N 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- 150000001242 acetic acid derivatives Chemical class 0.000 description 1
- 150000008065 acid anhydrides Chemical class 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 150000001263 acyl chlorides Chemical class 0.000 description 1
- 230000001464 adherent effect Effects 0.000 description 1
- 239000000443 aerosol Substances 0.000 description 1
- 230000004520 agglutination Effects 0.000 description 1
- 229910052783 alkali metal Inorganic materials 0.000 description 1
- 150000001340 alkali metals Chemical class 0.000 description 1
- 229910052784 alkaline earth metal Inorganic materials 0.000 description 1
- 150000001342 alkaline earth metals Chemical class 0.000 description 1
- 125000002947 alkylene group Chemical group 0.000 description 1
- SRVFFFJZQVENJC-IHRRRGAJSA-N aloxistatin Chemical compound CCOC(=O)[C@H]1O[C@@H]1C(=O)N[C@@H](CC(C)C)C(=O)NCCC(C)C SRVFFFJZQVENJC-IHRRRGAJSA-N 0.000 description 1
- 150000001408 amides Chemical group 0.000 description 1
- 230000003698 anagen phase Effects 0.000 description 1
- 229940035676 analgesics Drugs 0.000 description 1
- 150000001450 anions Chemical class 0.000 description 1
- 230000003042 antagnostic effect Effects 0.000 description 1
- 239000000730 antalgic agent Substances 0.000 description 1
- 230000000844 anti-bacterial effect Effects 0.000 description 1
- 230000001093 anti-cancer Effects 0.000 description 1
- 230000000843 anti-fungal effect Effects 0.000 description 1
- 239000002260 anti-inflammatory agent Substances 0.000 description 1
- 229940121363 anti-inflammatory agent Drugs 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 150000001558 benzoic acid derivatives Chemical class 0.000 description 1
- 235000019445 benzyl alcohol Nutrition 0.000 description 1
- KSCRVOKQPYZBHZ-IXPOFIJOSA-N benzyl n-[(2s)-1-[[(2s)-1-[[(2s)-1-(1,3-benzothiazol-2-yl)-1-oxo-3-[(3s)-2-oxopyrrolidin-3-yl]propan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-3-methyl-1-oxobutan-2-yl]carbamate Chemical compound N([C@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C[C@H]1C(NCC1)=O)C(=O)C=1SC2=CC=CC=C2N=1)C(C)C)C(=O)OCC1=CC=CC=C1 KSCRVOKQPYZBHZ-IXPOFIJOSA-N 0.000 description 1
- 239000012620 biological material Substances 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 238000009835 boiling Methods 0.000 description 1
- 159000000007 calcium salts Chemical class 0.000 description 1
- 230000000711 cancerogenic effect Effects 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 239000007963 capsule composition Substances 0.000 description 1
- 150000001721 carbon Chemical group 0.000 description 1
- 125000004432 carbon atom Chemical group C* 0.000 description 1
- 239000001569 carbon dioxide Substances 0.000 description 1
- 231100000315 carcinogenic Toxicity 0.000 description 1
- 210000005056 cell body Anatomy 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 230000032823 cell division Effects 0.000 description 1
- 230000010261 cell growth Effects 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 239000006285 cell suspension Substances 0.000 description 1
- 229940081733 cetearyl alcohol Drugs 0.000 description 1
- 238000013375 chromatographic separation Methods 0.000 description 1
- 150000001860 citric acid derivatives Chemical class 0.000 description 1
- 238000011278 co-treatment Methods 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 230000001472 cytotoxic effect Effects 0.000 description 1
- DIOQZVSQGTUSAI-NJFSPNSNSA-N decane Chemical group CCCCCCCCC[14CH3] DIOQZVSQGTUSAI-NJFSPNSNSA-N 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- HEDRZPFGACZZDS-MICDWDOJSA-N deuterated chloroform Substances [2H]C(Cl)(Cl)Cl HEDRZPFGACZZDS-MICDWDOJSA-N 0.000 description 1
- 238000007865 diluting Methods 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 239000000539 dimer Substances 0.000 description 1
- 239000006185 dispersion Substances 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 238000002330 electrospray ionisation mass spectrometry Methods 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 230000001804 emulsifying effect Effects 0.000 description 1
- 239000008387 emulsifying waxe Substances 0.000 description 1
- 239000006274 endogenous ligand Substances 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
- 125000002534 ethynyl group Chemical group [H]C#C* 0.000 description 1
- 230000001747 exhibiting effect Effects 0.000 description 1
- 238000012262 fermentative production Methods 0.000 description 1
- 239000012091 fetal bovine serum Substances 0.000 description 1
- 235000003599 food sweetener Nutrition 0.000 description 1
- 210000003918 fraction a Anatomy 0.000 description 1
- 229960002518 gentamicin Drugs 0.000 description 1
- 230000012010 growth Effects 0.000 description 1
- 150000008282 halocarbons Chemical class 0.000 description 1
- 125000005842 heteroatom Chemical group 0.000 description 1
- 238000002114 high-resolution electrospray ionisation mass spectrometry Methods 0.000 description 1
- 102000054896 human PML Human genes 0.000 description 1
- 206010020718 hyperplasia Diseases 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 230000006882 induction of apoptosis Effects 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 239000002054 inoculum Substances 0.000 description 1
- 238000007917 intracranial administration Methods 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000007913 intrathecal administration Methods 0.000 description 1
- 238000007914 intraventricular administration Methods 0.000 description 1
- 238000002372 labelling Methods 0.000 description 1
- 150000003893 lactate salts Chemical class 0.000 description 1
- JFOZKMSJYSPYLN-QHCPKHFHSA-N lifitegrast Chemical compound CS(=O)(=O)C1=CC=CC(C[C@H](NC(=O)C=2C(=C3CCN(CC3=CC=2Cl)C(=O)C=2C=C3OC=CC3=CC=2)Cl)C(O)=O)=C1 JFOZKMSJYSPYLN-QHCPKHFHSA-N 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 238000000622 liquid--liquid extraction Methods 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 239000011777 magnesium Substances 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 150000002688 maleic acid derivatives Chemical class 0.000 description 1
- 230000003211 malignant effect Effects 0.000 description 1
- 230000037323 metabolic rate Effects 0.000 description 1
- AFVFQIVMOAPDHO-UHFFFAOYSA-M methanesulfonate group Chemical class CS(=O)(=O)[O-] AFVFQIVMOAPDHO-UHFFFAOYSA-M 0.000 description 1
- NIQQIJXGUZVEBB-UHFFFAOYSA-N methanol;propan-2-one Chemical compound OC.CC(C)=O NIQQIJXGUZVEBB-UHFFFAOYSA-N 0.000 description 1
- 238000007069 methylation reaction Methods 0.000 description 1
- 230000000813 microbial effect Effects 0.000 description 1
- 150000007522 mineralic acids Chemical class 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 239000012452 mother liquor Substances 0.000 description 1
- 238000002703 mutagenesis Methods 0.000 description 1
- 231100000350 mutagenesis Toxicity 0.000 description 1
- QAPTWHXHEYAIKG-RCOXNQKVSA-N n-[(1r,2s,5r)-5-(tert-butylamino)-2-[(3s)-2-oxo-3-[[6-(trifluoromethyl)quinazolin-4-yl]amino]pyrrolidin-1-yl]cyclohexyl]acetamide Chemical compound CC(=O)N[C@@H]1C[C@H](NC(C)(C)C)CC[C@@H]1N1C(=O)[C@@H](NC=2C3=CC(=CC=C3N=CN=2)C(F)(F)F)CC1 QAPTWHXHEYAIKG-RCOXNQKVSA-N 0.000 description 1
- GVOISEJVFFIGQE-YCZSINBZSA-N n-[(1r,2s,5r)-5-[methyl(propan-2-yl)amino]-2-[(3s)-2-oxo-3-[[6-(trifluoromethyl)quinazolin-4-yl]amino]pyrrolidin-1-yl]cyclohexyl]acetamide Chemical compound CC(=O)N[C@@H]1C[C@H](N(C)C(C)C)CC[C@@H]1N1C(=O)[C@@H](NC=2C3=CC(=CC=C3N=CN=2)C(F)(F)F)CC1 GVOISEJVFFIGQE-YCZSINBZSA-N 0.000 description 1
- DIOQZVSQGTUSAI-UHFFFAOYSA-N n-butylhexane Natural products CCCCCCCCCC DIOQZVSQGTUSAI-UHFFFAOYSA-N 0.000 description 1
- 229930014626 natural product Natural products 0.000 description 1
- 239000000346 nonvolatile oil Substances 0.000 description 1
- 238000000655 nuclear magnetic resonance spectrum Methods 0.000 description 1
- 235000003715 nutritional status Nutrition 0.000 description 1
- GLDOVTGHNKAZLK-UHFFFAOYSA-N octadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCCCO GLDOVTGHNKAZLK-UHFFFAOYSA-N 0.000 description 1
- 125000002347 octyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 239000001053 orange pigment Substances 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- 150000003891 oxalate salts Chemical class 0.000 description 1
- 125000000466 oxiranyl group Chemical group 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- 229940049954 penicillin Drugs 0.000 description 1
- 239000012466 permeate Substances 0.000 description 1
- 229940066842 petrolatum Drugs 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- BXRNXXXXHLBUKK-UHFFFAOYSA-N piperazine-2,5-dione Chemical compound O=C1CNC(=O)CN1 BXRNXXXXHLBUKK-UHFFFAOYSA-N 0.000 description 1
- 125000004193 piperazinyl group Chemical group 0.000 description 1
- 238000000711 polarimetry Methods 0.000 description 1
- 229920001451 polypropylene glycol Polymers 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 238000011321 prophylaxis Methods 0.000 description 1
- 235000013772 propylene glycol Nutrition 0.000 description 1
- 239000001057 purple pigment Substances 0.000 description 1
- 229940109850 royal jelly Drugs 0.000 description 1
- 239000012488 sample solution Substances 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 238000010898 silica gel chromatography Methods 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 238000000638 solvent extraction Methods 0.000 description 1
- 239000001587 sorbitan monostearate Substances 0.000 description 1
- 235000011076 sorbitan monostearate Nutrition 0.000 description 1
- 229940035048 sorbitan monostearate Drugs 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 229960005322 streptomycin Drugs 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 150000003890 succinate salts Chemical class 0.000 description 1
- 239000011593 sulfur Chemical group 0.000 description 1
- 229910052717 sulfur Inorganic materials 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 239000000375 suspending agent Substances 0.000 description 1
- 239000003765 sweetening agent Substances 0.000 description 1
- 150000003892 tartrate salts Chemical class 0.000 description 1
- MHXBHWLGRWOABW-UHFFFAOYSA-N tetradecyl octadecanoate Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCCCCCCCCCCCCCC MHXBHWLGRWOABW-UHFFFAOYSA-N 0.000 description 1
- 238000009210 therapy by ultrasound Methods 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical class CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 1
- 238000000870 ultraviolet spectroscopy Methods 0.000 description 1
- 125000000391 vinyl group Chemical group [H]C([*])=C([H])[H] 0.000 description 1
- 238000010792 warming Methods 0.000 description 1
- 239000003871 white petrolatum Substances 0.000 description 1
Landscapes
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
The invention belongs to field of medicine and chemical technology, relate to indoline diketopiperazines spirocyclic compound, Preparation Method And The Use.Particularly, relate to formula I or its pharmacy acceptable salt, it has the framework types dimeric molecule structure formed by tetracyclic indole quinoline diketopiperazine and 1-oxaspiro [4,5] decane condensation, its volution six-ring has two ethylene oxide structures.The invention still further relates to the penicillium purpurogenum for the preparation of formula I.Confirm through experiment, this compounds can be used for preparing cytoskeletal protein inhibitor, cell death inducer, tumor cell proliferation inhibitor, tumor cytotoxicity agent or antitumor drug.Compound of the present invention has good anti-tumor activity.
Description
Technical Field
The invention belongs to the field of pharmaceutical chemicals, relates to a spiro compound, and particularly relates to an indoline diketopiperazine spiro compound, a composition containing the indoline diketopiperazine spiro compound, and a preparation method and application of the indoline diketopiperazine spiro compound.
Background
Tumor (Tumor) is a new organism formed by the clonal abnormal hyperplasia of a certain cell of local tissue which loses the normal regulation and control of the growth of the certain cell at the gene level under the action of various carcinogenic factors. Tumors are generally classified into two broad categories, benign and malignant. All malignant tumors are collectively referred to as cancer (cancer).
Spiro compounds are very abundant in structural types. Spiro [4,5] alone]The decane compound can form a plurality of different structure types because one or more positions of different positions on the spiro skeleton are substituted by heteroatoms such as oxygen, nitrogen, sulfur and the like. Having 1-oxaspiro [4,5]]Some spiro compounds having a decane skeleton structure have been known so far, but not many have been known which have two ethylene oxide structural fragments on the cyclohexane ring of such spiro skeleton. Wherein, the 6,7 position and the 9,10 position of the cyclohexane are respectively an ethylene oxide segment, the 8 position of the carbon is a ketocarbonyl group or sp3Known 1-oxaspiro [4,5] s having a carbon 2-position on the pentameric spiro ring as a lactone carbonyl or hemiacetal carbon, hybridized oxygen replacing carbon atoms]There are a limited number of the decanoids, among others, document 1 (H.W.Fehlhaberet al, Structure of aliphatic ketones, Anewantitiotic of anovellacetaltype, J.Am.chem.Soc.,1988,110(24): 8242-8244), document 2 (H.W.Fehlhaberet al, Araneosin, anoveliotic of Pseudomonas, II.Structure of aliphatic, J.Antibiot.,1988, XLI (12): 1785-1794) and document 3 (F.Koizumi, L.E.E.E.E.12, Anovello.891, anovelin-1 β, microorganism-2128-1, anovellout-898. C.E.898. C.C.C.C.898, C.C.C.C.C.A.C.A.A.A.A.C.A.A.A.C.A.A.A.C.A.A.A.A.A.A.A.A.1, A.C.A.A.C.C.A.A.A.C.A.A.C.A.A.A.A.A.A.A.A.A.A.A.A.A.A.A.A.A.A.A.A.A.A.A.A.A.A.A.A.A.A.C.A.A.A.A.A.A.A.A.A.A.A.A.A.A.A.A.C.A.A.A.A.A.A.A.A.A.B.A.A.A.A.A.A.C.A.A.C.A.A.A.A.A.A.A.A.A.C.A.A.B.A.A.C.]) Some of them also have a selective inhibitory action on interleukin-1 β converting enzyme activity and an action of inhibiting Lipopolysaccharide (LPS) from inducing THP-1 cells to secrete mature interleukin-1 β converting enzyme (see the above-mentioned document 3). document 5 (K.Roy, et al, Aranorosol Aandanorosol B, Wonewmetabolites from Pseudomonas aeruginosa Industrial science of producing, isolation, structureelucidathe synthetic biological properties, J.Antibiot.,1992,45(10): 1592-1598) describes five such carbon groups 8 as sp with an oxygen substituent3The hybrid carbon, carbon 2 is a lactone carbonyl or hemiacetal carbon, the carbon 3 position is connected with a spiro compound with an unsaturated dodecaaliphatic amide substituent carrying two branched methyl groups, and partial compounds have weak antibacterial and antifungal activities.
Many compounds belonging to different structural types are known as indole diketopiperazine compounds (see document 6[ Maryanmin, et al, synthetic research progress of indole diketopiperazine compounds, organic chemistry, 2010, 30(11): 1624-. Indoline diketopiperazines as their dihydro derivatives are also known to belong to various structural classes. However, the tetracyclic indoline diketopiperazine compound formed by connecting a five-membered ring in parallel between the five-membered nitrogen heterocycle of indoline and the six-membered nitrogen heterocycle of diketopiperazine is known to be less. Document 8 (K.Arai, et al, Structure of structural genes AandB, newalcoloid of structural genes Takeuchi, chem.Pharmn., 1989,37(11): 2937-2939), document 9 (A.G.Kozlovsky, et al, rugulosu of structural genes sAandB, dikettopira of structural genes of structural. Documents 10 and 14 (n.m. gomes, etal, eurocristine, anewdicketopiprazinedimer from the marinesponesent-assococcatedfuguseurotiumcristatum, phytochem.lett.,2012,5(4): 717-720) also describe 4 such compounds having a dimeric tetracyclinedione piperazine skeleton. Such partial compounds are known to have weak antitumor activity (see documents 8, 9 and 15[ Chayujing, et al, research on novel antitumor activity products of gentamicin-resistant mutant strain of Penicillium purpurogenum G59, J.Pharmacology, 2011, 38(3):216-222 ]), and are also known to have biological activity of competitively antagonizing the binding of substance P to NK-1 receptor (see document 10). Since substance P plays an important role as an endogenous ligand of NK-1 receptor in pain and inflammation processes, active substances that competitively antagonize substance P binding to NK-1 receptor have potential application values as non-addictive analgesics or anti-inflammatory agents.
However, no document has been found on indoline diketopiperazine spiro compounds having a dimer molecular skeleton formed by condensation-linking the tetracyclic indoline diketopiperazine skeleton structure and the 1-oxaspiro [4,5] decane skeleton structure according to the present invention described below in the molecule.
Disclosure of Invention
The present inventors succeeded in obtaining 2 mutant penicillium purpurogenum (penicillium purpurogenum) BD-1-3 and 3-f-31 strains by creative efforts and diligent efforts, and found indoline diketopiperazine spiro compounds represented by the following formula I from their fermentation products:
wherein,
the Arabic numerals represent corresponding positions of an indoline diketopiperazine skeleton and a spiro skeleton, and the structure is characterized in that molecules contain a dimeric molecular skeleton structure formed by condensation and connection of a tetracyclic indoline diketopiperazine skeleton and a 1-oxaspiro [4,5] decane skeleton, and a spiro six-membered ring of the dimeric molecular skeleton structure has two oxirane structures.
The inventor also surprisingly finds that the compound shown in the formula I can effectively kill tumor cells or inhibit the proliferation of the tumor cells, has good antitumor activity, and thus has good potential as an antitumor and anticancer medicament.
The following invention is thus provided:
one aspect of the present invention pertains to compounds of formula I as described above, or a pharmaceutically acceptable salt thereof,
wherein R is1-R3Each independently represents hydrogen, hydroxy, substituted or unsubstituted:
C1-10(e.g. C)1-6、C1-8) Linear or branched, saturated or unsaturated hydrocarbon radical, C1-10(e.g. C)1-6、C1-8) Linear or branched saturated or unsaturated hydrocarbyloxy radical, C2-18(e.g. C)2-6、C2-8) A linear or branched saturated or unsaturated aliphatic acyloxy group, or an aromatic acyloxy group (e.g., benzoyloxy group),
the substituent is selected from hydroxyl, halogen (such as fluorine, chlorine, bromine and iodine), nitro and benzyloxy, and the number of the substituent is 1-3 (such as 1, 2 and 3).
In an embodiment of the present invention, wherein,
R1represents substituted or unsubstituted C1-10(e.g. C)1-6、C1-8) Straight or branched chain alkyl, preferably 1- (2-methyl) octyl;
R2and R3Each independently represents hydrogen, hydroxy, substituted or unsubstituted:
C1-10(e.g. C)1-6、C1-8) Straight or branched alkoxy, C2-18(e.g. C)2-6、C2-8) A linear or branched saturated aliphatic acyloxy group, or an aromatic acyloxy group (e.g., benzoyloxy group),
the substituent is selected from hydroxyl, halogen (such as fluorine, chlorine, bromine and iodine), nitro and benzyloxy, and the number of the substituent is 1-3 (such as 1, 2 and 3).
In a specific embodiment of the present invention, wherein,
R1represents 1- (2-methyl) octyl;
R2and R3Each independently represents hydrogen, hydroxy, methoxy, ethoxy, acetoxy, galloyloxy, tribenzylgalloyloxy, benzoyloxy, p-nitrobenzoyloxy, p-chlorobenzoyloxy, or p-fluorobenzoyloxy.
In a particular embodiment of the invention, the substitution is ortho, para or meta.
In the present invention, said C1-10The linear or branched saturated or unsaturated hydrocarbon radicals being methyl, ethyl, C3Straight or branched alkyl, C4Straight or branched alkyl, C5Straight or branched alkyl, C6Straight or branched alkyl, C7Straight or branched alkyl, C8Straight or branched alkyl, C9Straight or branched alkyl, or C10An alkyl group such as a linear or branched alkyl group, or a vinyl group, C3Straight-chain or branched alkenyl, C4Straight-chain or branched alkenyl, C5Straight-chain or branched alkenyl, C6Straight-chain or branched alkenyl, C7Straight-chain or branched alkenyl, C8Straight-chain or branched alkenyl, C9Straight or branched alkenyl, or C10Alkylene group such as linear or branched alkylene group, or ethynyl group, C3Alkynyl radical, C4Straight or branched alkynyl, C5Straight or branched alkynyl, C6Straight or branched alkynyl, C7Straight or branched alkynyl, C8Straight or branched alkynyl, C9Straight or branched alkynyl, or C10Straight or branched alkynyl, or phenyl, substituted phenyl, benzyl, substituted benzyl, C8Straight-chain or branched aromatic hydrocarbon group, C9Straight or branched aromatic hydrocarbon radicals, or C10An aromatic hydrocarbon group such as a linear or branched aromatic hydrocarbon group.
In the present invention, said C1-10The linear or branched saturated or unsaturated hydrocarbyloxy groups being methoxy, ethoxy, C3Straight or branched alkoxy, C4Straight or branched alkoxy, C5Straight or branched alkoxy, C6Straight or branched alkoxy, C7Straight or branched alkoxy, C8Straight or branched alkoxy, C9Linear or branched alkoxy, or C10Linear or branched alkoxy, or is ethyleneoxy, C3Linear or branched alkenyloxy, C4Linear or branched alkenyloxy, C5Linear or branched alkenyloxy, C6Linear or branched alkenyloxy, C7Linear or branched alkenyloxy, C8Linear or branched alkenyloxy, C9Linear or branched alkenyloxy, or C10An alkenyloxy group such as a linear or branched alkenyloxy group, or an acetylenecarbonyloxy group, C3Alkenoxy radical, C4Straight or branched alkynyloxy, C5Straight or branched alkynyloxy, C6Straight or branched alkynyloxy, C7Straight or branched alkynyloxy, C8Straight or branched alkynyloxy, C9Straight or branched alkynyloxy, or C10Straight-chain or branched alkynyloxy such as phenoxyl, substituted phenoxyl, benzyloxy, substituted benzyloxy, and C8Straight or branched chain arene oxy, C9Linear or branched areneoxy, or C10An aromatic hydrocarbon oxy group such as a straight chain or branched chain aromatic hydrocarbon oxy group.
In the present invention, said C2-18The linear or branched saturated or unsaturated aliphatic or aromatic acyloxy group is formyloxy, acetyloxy, propionyloxy, acryloyloxy, butyryloxy, isobutyryloxy, valeryloxy, formyloxy, or a mixture thereof,Fatty acyloxy group such as isovaleryloxy, succinyloxy, octyloxy, decyloxy, royal jelly acyloxy, lauroyloxy, 3-hydroxylauroyloxy, myristoyloxy, palmitoyloxy, stearoyloxy, oleoyloxy, or linoleoyloxy, or benzoyloxy, substituted benzoyloxy, phenylacetyloxy, substituted phenylacetyloxy, or 2-position C substituted by straight or branched chain2-8Substituted phenylacetyloxy, phenylpropionyloxy, 2-substituted by a straight or branched chain C2-7Substituted phenylpropoyloxy, substituted in position 3 by a straight or branched chain C2-7Substituted phenylpropoyloxy, 2-and 3-positions simultaneously substituted by a straight-chain or branched C2-6Substituted phenylpropoyloxy, phenylbutyloxy, substituted in position 2 by a straight or branched chain C2-6Substituted phenylbutyloxy, substituted in position 3 by a straight or branched chain C2-6Substituted phenylbutyloxy, substituted in position 4 by a straight or branched chain C2-6Substituted phenylbutyryloxy, the 2 and 3 or2 and 4 or 3 and 4 positions being simultaneously substituted by a straight-chain or branched C2-5Substituted phenylbutyloxy, or simultaneous substitution of the 2-to 4-positions by a straight-chain or branched C2-4Substituted phenylbutyloxy and the like.
The second aspect of the invention relates to penicillium purpurogenum BD-1-3(Penicillium purpurogenum BD-1-3), the preservation number is CGMCC No.4284, the preservation date is 11.1 days 2010, the preservation unit is China general microbiological culture Collection center (CGMCC), the address is No. 3 of Xilu No. 1 of Beijing Kogyo Chaoyang district, the institute of microbiology of China academy of sciences, and the postal code is 100101.
The strain is a mutant strain BD-1-3 obtained by performing diethyl sulfate mutagenesis on a wild Penicillium purpurogenum G59 strain of Penicillium fungus of Penicillium purpurogenum which is separated from a sample of intertidal zone sea mud of Tianjin pond donkey colal river Bohai gulf and identified as Penicillium purpurogenum through taxonomic research. It has the following microbiological characteristics:
after the cells are inoculated on a PDA plate culture medium by streaking and cultured for 3-5 days at 28 ℃, light gray light cyan colonies which grow slightly gray can be seen from the front side of the plate, and orange reddish or pink purple pigment which permeates the bottom of the culture can be seen from the back side of the plate;
culturing the colonies on a Chachi culture medium at 25 deg.C for 12 days with diameter of 17-30mm, and keeping the diameter flat or nearly flat or having several concentric rings; the texture is velvet or flocculent; the conidium surface is dark gray green or dark green, and is similar to olive lemon color, brown olive color or slightly dark olive green; mycelium is orange, yellow or orange-red; dark red, orange or purple red on the back; conidiophores occur in the substrate, fewer aerial hyphae occur, the conidiophores stem (70-) 100-; the broom-shaped branches are double-rotor, even three-rotor or single-rotor, and are close to each other and are nearly parallel; 4-8 stem bases are arranged in each wheel, 9.0-13(-14) multiplied by 2.5-3.0 mu m; each round of phialides has 4-6 phialides, 9.5-13 x (1.8-)2.0-2.4 mu m, and stems are obvious in shape of needles; conidiophores are elliptical, when fully mature, part of conidiophores are approximately spherical, 2.8-3.5(-4.0) multiplied by 2.2-3.0 mu m, and the wall is smooth or slightly rough; the conidiophore chain is loose and is forked or nearly cylindrical.
The third aspect of the invention relates to penicillium purpurogenum3-f-31 (penicillium purpurogenum3-f-31), the preservation number is CGMCC No.7286, the preservation date is 3.7.2013, the preservation unit is China general microbiological culture Collection center (CGMCC), the address is No. 3 of West Lu No. 1 of the Beijing Kogyo Ind area, the institute of microbiology of the Chinese academy of sciences, and the zip code is 100101.
The strain is a neomycin resistant mutant strain 3-f-31 of penicillium purpurogenum G59, which is obtained by separating a sample of intertidal sea mud from Tianjin pond donkey colal river Bohai gulf of Penicillium purpurogenum, identifying the sample as a wild penicillium purpurogenum G59 strain of penicillium purpurogenum through taxonomic research and screening 5mg/ml neomycin resistance in 50% (v/v) DMSO. It has the following microbiological characteristics:
after the culture is carried out for 3-5 days at 28 ℃ by streak inoculation on a PDA plate culture medium, a light gray light cyan colony which is slightly cyan and is grown can be seen from the front side of the plate, the color of the bacterial colony is more slightly cyan and has obvious difference compared with the blue mould BD-1-3, and the orange pigment slightly yellow at the bottom of the permeation culture can be seen from the back side of the plate;
culturing the colonies on a Chachi culture medium at 25 deg.C for 12 days with diameter of 17-30mm, and keeping the diameter flat or nearly flat or having several concentric rings; the texture is velvet or flocculent; the conidium surface is dark gray green or dark green, and is similar to olive lemon color, brown olive color or slightly dark olive green; mycelium is orange, yellow or orange-red; dark red, orange or purple red on the back; conidiophores occur in the substrate, fewer aerial hyphae occur, the conidiophores stem (70-) 100-; the broom-shaped branches are double-rotor, even three-rotor or single-rotor, and are close to each other and are nearly parallel; 4-8 stem bases are arranged in each wheel, 9.0-13(-14) multiplied by 2.5-3.0 mu m; each round of phialides has 4-6 phialides, 9.5-13 x (1.8-)2.0-2.4 mu m, and stems are obvious in shape of needles; conidiophores are elliptical, when fully mature, part of conidiophores are approximately spherical, 2.8-3.5(-4.0) multiplied by 2.2-3.0 mu m, and the wall is smooth or slightly rough; the conidiophore chain is loose and is forked or nearly cylindrical.
A fourth aspect of the present invention relates to a process for the preparation of compound 1 and/or 2, comprising the steps of:
fermenting and culturing the Penicillium purpurogenum BD-1-3 or 3-f-31 to obtain a fermented product containing the compound 1 and/or 2, and separating and purifying the fermented product to obtain the compound 1 and/or 2;
wherein said compound 1 is a compound of formula I according to the first aspect of the invention, wherein R1=1- (2-methyl) octyl radical, R2=OH,R3= H; wherein said compound 2 is a compound of formula I according to the first aspect of the invention, wherein R1=1- (2-methyl) octyl radical, R2=R3=OH。
Specifically, the separation and purification includes conventional methods for separation and purification of natural products, such as liquid-liquid extraction, column chromatography, thin layer chromatography, high performance liquid chromatography, recrystallization, and the like, which are well known to those skilled in the art.
Other production strains of the genus Penicillium capable of producing compounds 1 and/or 2 may also be used for the fermentative culture.
In one embodiment of the present invention, the preparation method comprises the following steps:
1) carrying out fermentation culture on the penicillium purpurogenum to obtain fermentation liquor;
2) filtering the fermentation liquor to obtain filtrate and thalli;
3) extracting the filtrate obtained in the step 2) with ethyl acetate to obtain an ethyl acetate extract of the filtrate;
4) suspending the thallus obtained in the step 2) in 50-95% (v/v) acetone aqueous solution, crushing thallus cells, leaching and filtering, concentrating the filtrate under reduced pressure until the filtrate does not contain acetone, and extracting with ethyl acetate to obtain an ethyl acetate extract;
5) combining the ethyl acetate extracts obtained in the steps 3) and 4), and concentrating under reduced pressure to dryness to obtain an ethyl acetate total extract;
6) dissolving ethyl acetate total extract with mixed solvent of chloroform-methanol at volume ratio of 1:1, or dissolving methanol soluble fraction obtained by dissolving ethyl acetate total extract with a large amount of methanol with mixed solvent of dichloromethane-methanol at volume ratio of 1:2, separating with 100-mesh 200-mesh silica gel column, performing gradient elution under reduced pressure with petroleum ether-chloroform-methanol solvent system or petroleum ether-dichloromethane-acetone-methanol solvent system as eluent to obtain crude component containing the compound, and separating with two times of Sephadex LH-20 column chromatography (first eluting with 95% ethanol by volume fraction and second eluting with mixed solvent of chloroform-methanol at volume ratio of 1: 1) or one time of Sephadex LH-20 column chromatography (eluting with 95% ethanol by volume fraction) and one time of reversed phase silica gel column chromatography ODS (eluting with water-methanol-acetone solvent system gradient elution) Elution) to obtain a column chromatography component containing the main component of the compound;
7) the column chromatography fractions containing the compound were separated and purified by either two reverse phase HPLC (C18 column eluting with methanol-water volume fraction 80:20 for the first time and 86:14 or 82:18 for the second time) or one HPLC (C18 column eluting with 81:19 methanol-water volume fraction) to give the compound.
In one embodiment of the present invention, the preparation method, wherein the aqueous acetone solution in the step 4) is an aqueous acetone solution containing 70% to 90% (v/v) of acetone; specifically, it is an aqueous acetone solution of 75% to 85% (v/v) of acetone, for example, an aqueous acetone solution of 75%, 76%, 77%, 78%, 79%, 80%, 81%, 82%, 83%, 84%, or 85% (v/v).
In one embodiment of the present invention, the preparation method, wherein the aqueous acetone solution in the step 4) is an aqueous acetone solution containing 55% to 75% (v/v) of acetone; specifically, it is an aqueous acetone solution containing 60% to 70% (v/v) of acetone, for example, an aqueous acetone solution containing 60%, 61%, 62%, 63%, 64%, 65%, 66%, 67%, 68%, 69%, or 70% (v/v) of acetone.
A fifth aspect of the present invention relates to a method for producing a derivative of compound 1 or2, comprising the steps of:
respectively carrying out derivatization reaction on the compound 1 or2 of the invention and appropriate chemical reaction reagents such as halogenated hydrocarbon, ester, acid anhydride, acyl chloride and the like, and separating and purifying reaction products to obtain the derivatives;
wherein said compound 1 is a compound of formula I according to the first aspect of the invention, wherein R1=1- (2-methyl) octyl radical, R2=OH,R3= H; wherein said compound 2 is a compound of formula I according to the first aspect of the invention, wherein R1=1- (2-methyl) octyl radical, R2=R3=OH。
Specifically, the separation and purification includes conventional methods for separation and purification, such as column chromatography, thin layer chromatography, high performance liquid chromatography, recrystallization, and the like, which are well known to those skilled in the art.
In one embodiment of the present invention, the preparation method comprises the following steps:
1) dissolving the compound 1 or2 with acetone or anhydrous pyridine;
2) performing derivatization reaction with methyl iodide, diethyl sulfate, acetic anhydride, gallic acid, tribenzyl galloyl chloride, benzoyl chloride, p-nitrobenzoyl chloride, p-chlorobenzoyl chloride or p-fluorobenzoyl chloride for 1-48 h or 3-10 days under the conditions of keeping out of the sun or heating to keep out of the sun at room temperature and adding hydrochloric acid for catalysis or not adding hydrochloric acid for catalysis;
3) separating and purifying the reaction product by using a silica gel thin layer chromatography (a mixed solvent of chloroform and methanol in a volume ratio of 80: 20-99: 1 is used as a developing agent) to prepare the compound.
In one embodiment of the present invention, the production method, wherein the "warming" in the step 2) means heating to maintain the reaction temperature at 30 ℃ to 80 ℃; specifically, the reaction temperature is maintained at 40 ℃ to 60 ℃, e.g., 40 ℃, 50 ℃, or 60 ℃.
A sixth aspect of the present invention relates to a composition comprising a compound of formula I according to any one of the first aspect of the present invention or a pharmaceutically acceptable salt thereof, optionally together with one or more pharmaceutically acceptable carriers or excipients. In particular, the composition is a pharmaceutical composition. The composition or the pharmaceutical composition can be used for resisting tumors or inhibiting the proliferation of tumor cells or killing the tumor cells.
In a further aspect, the invention relates to the use of a compound of formula I according to any one of the first aspect of the invention or a pharmaceutically acceptable salt thereof as a tool for the preparation of cytoskeletal protein inhibitors, apoptosis inducers, tumor cell proliferation inhibitors, or tumor cell killing agents, as required in life science research such as tumor molecular biology; further, the tumor cell is a leukemia cell or a cancer cell derived from epithelium (for example, a cervical cancer cell, a gastric cancer cell, a breast cancer cell, a lung cancer cell, a liver cancer cell, or a colon cancer cell); still further, the leukemia cells are chronic myelogenous leukemia cells or acute promyelocytic leukemia cells; furthermore, the tumor cells are human chronic myelogenous leukemia K562 cells, human acute promyelocytic leukemia HL-60 cells, human cervical cancer HeLa cells, human gastric cancer BGC-823 cells, or human breast cancer MCF-7 cells.
A further aspect of the present invention relates to the use of a compound of formula I according to any one of the first aspect of the present invention or a pharmaceutically acceptable salt thereof, or a composition according to any one of the sixth aspect of the present invention, in the manufacture of a medicament or agent for killing or inhibiting proliferation of tumor cells; further, the tumor cell is a leukemia cell or a cancer cell derived from epithelium (for example, a cervical cancer cell, a gastric cancer cell, a breast cancer cell, a lung cancer cell, a liver cancer cell, or a colon cancer cell); still further, the leukemia cells are chronic myelogenous leukemia cells or acute promyelocytic leukemia cells.
In an embodiment of the present invention, the tumor cell is a human chronic myelogenous leukemia K562 cell, a human acute promyelocytic leukemia HL-60 cell, a human cervical cancer HeLa cell, a human gastric cancer BGC-823 cell, or a human breast cancer MCF-7 cell.
A further aspect of the present invention relates to a method of killing tumor cells or inhibiting proliferation of tumor cells in vivo or in vitro comprising the step of administering an effective amount of a compound of formula I according to any one of the first aspect of the present invention or a pharmaceutically acceptable salt thereof, or a composition according to any one of the sixth aspect of the present invention; further, the tumor cell is a leukemia cell or a cancer cell derived from epithelium (for example, a cervical cancer cell, a gastric cancer cell, a breast cancer cell, a lung cancer cell, a liver cancer cell, or a colon cancer cell); still further, the leukemia cells are chronic myelogenous leukemia cells or acute promyelocytic leukemia cells.
In an embodiment of the present invention, the tumor cell is a human chronic myelogenous leukemia K562 cell, a human acute promyelocytic leukemia HL-60 cell, a human cervical cancer HeLa cell, a human gastric cancer BGC-823 cell, or a human breast cancer MCF-7 cell.
A further aspect of the invention relates to the use of a compound of formula I according to any one of the first aspect of the invention or a pharmaceutically acceptable salt thereof, or a composition according to any one of the sixth aspect of the invention, in the manufacture of an anti-neoplastic medicament; for example, the tumor is leukemia or a cancer derived from epithelium (e.g., cervical cancer, gastric cancer, breast cancer, lung cancer, liver cancer, or colon cancer); further, the leukemia is chronic myelogenous leukemia, acute promyelocytic leukemia.
A further aspect of the present invention relates to a method of treatment and/or prophylaxis and/or co-treatment of cancer comprising the step of administering to a subject an effective amount of a compound of formula I according to any one of the first aspect of the present invention or a pharmaceutically acceptable salt thereof, or a composition according to any one of the sixth aspect of the present invention; the cancer is leukemia or cancer derived from epithelium (such as cervical cancer, gastric cancer, breast cancer, lung cancer, liver cancer, or colon cancer); further, the leukemia is chronic myelogenous leukemia and acute promyelocytic leukemia.
The compound of the formula I is tested to inhibit human chronic myelogenous leukemia K562 cells, human promyelocytic leukemia HL-60 cells, human cervical carcinoma HeLa cells, human breast cancer MCF-7 cells and human gastric cancer BGC-823 cells by adopting an MTT method. Experiments prove that the compound of the formula I can obviously inhibit the proliferation of various human cancer cells in vitro, thereby having the anti-tumor effect.
A further aspect of the present invention relates to the use of a penicillium purpurogenum as defined above for the preparation of compounds 1 and/or 2 according to the invention; in particular to application of Penicillium purpurogenum BD-1-3 with the preservation number of CGMCCNo.4284 and Penicillium purpurogenum3-f-31 with the preservation number of CGMCCNo.7286 in preparing the compound 1 and/or 2 of the invention.
The compound of the formula I can be prepared into antitumor drugs by being compatible with various pharmaceutically acceptable carriers, excipients or auxiliary materials, and is used for treating tumors.
The compounds of the present invention may be administered alone or in the form of a pharmaceutical composition. The route of administration may be oral, parenteral or topical. The pharmaceutical composition can be formulated into various suitable dosage forms according to the administration route.
Pharmaceutical compositions of the compounds of the present invention may be administered in any of the following ways: oral, aerosol inhalation, rectal, nasal, buccal, topical, parenteral, e.g. subcutaneous, intravenous, intramuscular, intraperitoneal, intrathecal, intraventricular, intrasternal and intracranial injection or infusion, or via an external reservoir. Among them, oral, intraperitoneal or intravenous administration is preferable.
When administered orally, the compounds of the present invention may be formulated in any orally acceptable dosage form, including but not limited to tablets, capsules, aqueous solutions or suspensions. Among these, carriers for tablets generally include lactose and corn starch, and additionally, lubricating agents such as magnesium stearate may be added. Diluents used in capsule formulations generally include lactose and dried corn starch. Aqueous suspension formulations are generally prepared by mixing the active ingredient with suitable emulsifying and suspending agents. Optionally, some sweetener, aromatic or colorant may be added into the above oral preparation.
When applied topically to the skin, the compounds of the present invention may be formulated in a suitable ointment, lotion, or cream formulation wherein the active ingredient is suspended or dissolved in one or more carriers. Carriers that may be used in ointment formulations include, but are not limited to: mineral oil, liquid petrolatum, white petrolatum, propylene glycol, polyethylene oxide, polypropylene oxide, emulsifying wax and water; carriers that can be used in lotions or creams include, but are not limited to: mineral oil, sorbitan monostearate, tween 60, cetyl esters wax, cetearyl alcohol, 2-octyldodecanol, benzyl alcohol and water.
The compounds of the present invention may also be administered in the form of sterile injectable preparations, including sterile injectable aqueous or oleaginous suspensions or solutions. Among the carriers and solvents that may be employed are water, ringer's solution and isotonic sodium chloride solution. In addition, the sterilized fixed oil may also be employed as a solvent or suspending medium, such as a monoglyceride or diglyceride.
It is further noted that the dosage and method of administration of the compounds of the present invention will depend upon a variety of factors including the age, weight, sex, physical condition, nutritional status, the activity level of the compound, time of administration, metabolic rate, severity of the condition, and the subjective judgment of the treating physician. The preferred dosage is between 0.01-100 mg/kg body weight/day.
In the present invention,
the term "pharmaceutically acceptable salt" refers to pharmaceutically acceptable inorganic or organic salts. The compounds having a basic group in formula I of the present invention may form pharmaceutically acceptable salts with inorganic acids, such as sulfate, hydrochloride, hydrobromide, phosphate; pharmaceutically acceptable salts can also be formed with organic acids such as acetates, oxalates, citrates, gluconates, succinates, tartrates, p-toluenesulfonates, methanesulfonates, benzoates, lactates, maleates, and the like. The compounds having an acidic group in formula I of the present invention may form pharmaceutically acceptable salts with alkali metals or alkaline earth metals, preferably but not limited to sodium, potassium, magnesium or calcium salts.
The term "effective amount" refers to a dose that achieves treatment, prevention, alleviation and/or amelioration of a disease or disorder described herein in a subject.
The term "subject" may refer to a patient or other animal, particularly a mammal, e.g., a human, dog, monkey, cow, horse, etc., that receives a compound of formula I or a pharmaceutical composition of any one of the invention to treat, prevent, alleviate and/or ameliorate a disease or disorder described herein.
The term "disease and/or disorder" refers to a physical condition of the subject that is associated with the disease and/or disorder of the present invention.
Advantageous effects of the invention
The compound of the formula I can effectively kill tumor cells or inhibit the proliferation of the tumor cells, has good antitumor activity and has the potential of being used as an antitumor drug.
Biological material relating to preservation
The Penicillium purpurogenum BD-1-3 has been preserved in China general microbiological culture Collection center (CGMCC) on 11/1 2010; the preservation address is Beijing, Chaoyang district, Beichen Xilu No. 1 institute No. 3, China academy of sciences microbiological research institute, postal code 100101; the preservation number is CGMCC No. 4284; the classification was named Penicillium purpurogenum (Penicillium purpurogenum).
The penicillium purpurogenum3-f-31 has been preserved in China general microbiological culture Collection center (CGMCC) in 2013, 3, 7 and 7 months; the preservation address is Beijing, Chaoyang district, Beichen Xilu No. 1 institute No. 3, China academy of sciences microbiological research institute, postal code 100101; the preservation number is CGMCC No. 7286; the classification was named Penicillium purpurogenum (Penicillium purpurogenum).
Detailed Description
Embodiments of the present invention will be described in detail below with reference to examples, but those skilled in the art will appreciate that the following examples are only illustrative of the present invention and should not be construed as limiting the scope of the present invention. The examples, in which specific conditions are not specified, were conducted under conventional conditions or conditions recommended by the manufacturer. The reagents or instruments used are not indicated by manufacturers, and are all conventional products available on the market.
In the following examples of the present invention,
the compound of the present invention, hereinafter referred to as compound 1, has the following structure as identified by nuclear magnetic resonance or the like: a compound of formula I wherein R1=1- (2-methyl) octyl radical, R2=OH,R3= H; the compounds of the invention, hereinafter referred to as Compound 2Nuclear magnetic resonance and the like have the following structures: a compound of formula I wherein R1=1- (2-methyl) octyl radical, R2=R3=OH;
Wherein the Arabic numerals represent the index; r1The octyl group of (A) is in the order of 5"→ 12" on the carbon atom bonded to carbon 4", and 14" on the 2-methyl group.
The compounds of the present invention, hereinafter referred to as compound 1a, have the following structure: the compound of the formula I, wherein R1=1- (2-methyl) octyl radical, R2=OCH3,R3= H; the compounds of the present invention, hereinafter referred to as compound 1b, have the following structure: the compound of the formula I, wherein R1=1- (2-methyl) octyl radical, R2=OCH2CH3,R3= H; the compounds of the present invention, hereinafter referred to as compound 1c, have the following structure: the compound of the formula I, wherein R1=1- (2-methyl) octyl radical, R2=OCOCH3,R3= H; the compounds of the present invention, hereinafter referred to as compound 1d, have the following structure: the compound of the formula I, wherein R1=1- (2-methyl) octyl radical, R2= galloyloxy, R3= H; the compounds of the present invention, hereinafter referred to as compound 1e, have the following structure: the compound of the formula I, wherein R1=1- (2-methyl) octyl radical, R2= Tribenzyl Galloyloxy, R3= H; the compounds of the present invention, hereinafter referred to as compound 1f, have the following structure: the compound of the formula I, wherein R1=1- (2-methyl) octyl radical, R2= benzoyloxy, R3= H; the compound of the invention, hereinafter referred to as compound 1g, has the following structure: the compound of the formula I, wherein R1=1- (2-methyl) octyl radical, R2= p-nitrobenzoyloxy, R3= H; the compounds of the present invention, hereinafter referred to as compound 1h, have the following structure: the compound of the formula I, wherein R1=1- (2-methyl) octyl radical, R2= p-chlorobenzoyloxy, R3= H; the compounds of the present invention, hereinafter referred to as compound 1i, have the following structure: the compound of the formula I, wherein R1=1- (2-methyl) octyl radical, R2= p-fluorobenzoyloxy, R3=H。
The compounds of the present invention, hereinafter referred to as compound 2a, have the following structure: the compound of the formula I, wherein R1=1- (2-methyl) octyl radical, R2=OH,R3=OCH3(ii) a The compounds of the present invention, hereinafter referred to as compound 2b, have the following structure: the compound of the formula I, wherein R1=1- (2-methyl) octyl radical, R2=R3=OCH3(ii) a The compounds of the present invention, hereinafter referred to as compound 2c, have the following structure: the compound of the formula I, wherein R1=1- (2-methyl) octyl radical, R2=OH,R3=OCH2CH3(ii) a The compounds of the present invention, hereinafter referred to as compound 2d, have the following structure: the compound of the formula I, wherein R1=1- (2-methyl) octyl radical, R2=R3=OCH2CH3(ii) a The compounds of the present invention, hereinafter referred to as compound 2e, have the following structure: the compound of the formula I, wherein R1=1- (2-methyl) octyl radical, R2=OH,R3=OCOCH3(ii) a The compounds of the present invention, hereinafter referred to as compound 2f, have the following structure: the compound of the formula I, wherein R1=1- (2-methyl) octyl radical, R2=R3=OCOCH3(ii) a The compound of the invention, hereinafter referred to as compound 2g, has the following structure: the compound of the formula I, wherein R1=1- (2-methyl) octyl radical, R2=OH,R3= galloyloxy; the compounds of the present invention, hereinafter referred to as compound 2h, have the following structure: the compound of the formula I, wherein R1=1- (2-methyl) octyl radical, R2=R3= galloyloxy; the compounds of the present invention, hereinafter referred to as compound 2i, have the following structure: the compound of the formula I, wherein R1=1- (2-methyl) octyl radical, R2=OH,R3= Tribenzyl Gallic acidAn acyloxy group; the compounds of the present invention, hereinafter referred to as compound 2j, have the following structure: the compound of the formula I, wherein R1=1- (2-methyl) octyl radical, R2=R3= tribenzylgalloyloxy; the compounds of the present invention, hereinafter referred to as compound 2k, have the following structure: the compound of the formula I, wherein R1=1- (2-methyl) octyl radical, R2=OH,R3= benzoyloxy; the compounds of the present invention, hereinafter referred to as compound 2l, have the following structure: the compound of the formula I, wherein R1=1- (2-methyl) octyl radical, R2=R3= benzoyloxy; the compounds of the present invention, hereinafter referred to as compound 2m, have the following structure: the compound of the formula I, wherein R1=1- (2-methyl) octyl radical, R2=OH,R3= p-nitrobenzoyloxy; the compounds of the present invention, hereinafter referred to as compound 2n, have the following structure: the compound of the formula I, wherein R1=1- (2-methyl) octyl radical, R2=R3= p-nitrobenzoyloxy; the compounds of the present invention, hereinafter referred to as compound 2o, have the following structure: the compound of the formula I, wherein R1=1- (2-methyl) octyl radical, R2=OH,R3= p-chlorobenzoyloxy; the compounds of the present invention, hereinafter referred to as compound 2p, have the following structure: the compound of the formula I, wherein R1=1- (2-methyl) octyl radical, R2=R3= p-chlorobenzoyloxy; the compounds of the present invention, hereinafter referred to as compound 2q, have the following structure: the compound of the formula I, wherein R1=1- (2-methyl) octyl radical, R2=OH,R3= p-fluorobenzoyloxy; the compounds of the present invention, hereinafter referred to as compound 2r, have the following structure: the compound of the formula I, wherein R1=1- (2-methyl) octyl radical, R2=R3= p-fluorobenzoyloxy group.
In the following examples of the present invention,
the melting point was measured with X-4 type precision melting point measuring instrument of Beijing Tian Di Yu science and technology, Ltd, and the temperature was not corrected. The specific polarimetry was measured by PolAAr3005 polarimeter, JASCOP2000 polarimeter, JASCO, Japan, or Autopoli polarimeter, RudolphResearch, USA. Positive and negative ion ESI-MS and HR-ESI-MS were measured with an API3000 liquid chromatography-mass spectrometer (AB, USA) and a 6520Q-TOF mass spectrometer (Agilent, USA), respectively. The Ultraviolet (UV) spectrum was measured with a Cintra20 ultraviolet visible spectrophotometer, GBC Australia, and the Infrared (IR) spectrum was measured with a Tensor27 infrared spectrometer, Bruker, Germany. NMR spectra were measured with a superconducting NMR spectrometer of JNM-ECA-400 model, JEOL, Japan, and INOVA600 model, Varian, USA. The circular double dispersion (CD) spectrum was measured with a JASCOJ-815 circular dichrograph, JASCO, Japan, or a MOS-450 circular dichrograph, biologicScience, France.
All solvents used in all experiments were of analytical grade, with petroleum ether boiling point range of 60-90 ℃.
Example 1: microbial fermentation culture and preparation of compound 1 and compound 2
1. Fermentation culture and extraction treatment of fermented product
1) Production strain
The strain used for the fermentative production of compounds 1 and 2 in this example was Penicillium purpurogenum BD-1-3(Penicillium purpurogenum BD-1-3) deposited in the general microbiological center of the China Committee for culture Collection of microorganisms with the accession number of 4284 (CGMCCNo.4283).
2) Fermentation culture
A test tube slant is prepared from PDA culture medium (composed of glucose 2%, agar 2%, and NaCl1.5% and prepared from 20% potato decoction) of Penicillium purpurogenum BD-1-3 stored in a refrigerator at 4 deg.C by scraping appropriate amount of spores with inoculating loop under aseptic condition, streaking, inoculating onto newly prepared PDA solid culture medium plate, and activating and culturing at 28 deg.C for 4 days. From the test tube slant after 4 days of activation culture, an appropriate amount of cells were scraped with an inoculating loop, inoculated into 1 500ml Erlenmeyer flask containing 200ml of a liquid fermentation medium (composition: glucose 2%, maltose 1%, mannitol 2%, glutamic acid 1%, peptone 0.5%, yeast extract powder 0.3%), and subjected to primary seed culture in a shaker at 28 ℃ and 200rpm for 48 hours. The culture solution was inoculated at 5% inoculum size into 15 500ml Erlenmeyer flasks each containing 200ml of a liquid fermentation medium (consisting of glucose 2%, maltose 1%, mannitol 2%, glutamic acid 1%, peptone 0.5%, yeast extract 0.3%), and subjected to secondary seed culture at 28 ℃ for 48 hours in a shaker at 200 rpm. The culture solution was inoculated as a seed in an inoculation amount of 5% to 200 500ml Erlenmeyer flasks each containing 200ml of a liquid fermentation medium (composition: glucose 2%, maltose 1%, mannitol 2%, glutamic acid 1%, peptone 0.5%, yeast extract 0.3%), and subjected to shake culture at 28 ℃ and 200rpm for 12 days to obtain about 40L in total of the fermentation broth.
2. Extraction treatment and preparation of ethyl acetate extract
About 40L of the total fermentation broth was filtered through 4 layers of gauze to separate the filtrate and the biomass. About 36L of the filtrate was directly extracted with an equal volume of ethyl acetate 3 times, and the resulting ethyl acetate extracts were combined and concentrated under reduced pressure to give an ethyl acetate extract of the filtrate. The bacteria are fully stirred and suspended by 10L of 80% (v/v) acetone aqueous solution, the bacteria are crushed by ultrasonic for 2h, extracted for 12h at room temperature, filtered by 4 layers of gauze, and the aqueous acetone extracting solution is obtained by filtration. The same extraction of the cells was repeated 3 times in total, and the resulting aqueous acetone extracts were combined and concentrated under reduced pressure until acetone was not contained. About 5L of the residual water layer was extracted with an equal volume of ethyl acetate 3 times, and the resulting ethyl acetate extracts were combined and concentrated under reduced pressure to give an ethyl acetate extract of the cells. Silica gel thin layer chromatography detection results show that the product spots contained in the filtrate and the ethyl acetate extract of the thalli are basically the same, so the two extracts are combined and then are concentrated under reduced pressure to be dry, and 40g of ethyl acetate total extract is obtained. The inhibition rate of the extract on K562 cells under the concentration of 100 mu g/ml is 68.7 percent (the inhibition rate test method is the same as that of the example 4).
3. Separation of ethyl acetate extract and preparation of column chromatography component containing target compound
40g of the total ethyl acetate extract is dissolved by using a proper amount of chloroform-methanol (volume ratio is 1: 1) mixed solvent, 60g of silica gel (100-. Collecting and merging corresponding eluents for concentration according to a thin-layer chromatography detection result to obtain 13 components: fr-1(0.9g, petroleum ether-chloroform volume ratio 2:1 solvent elution fraction), Fr-2(1.3g, petroleum ether-chloroform volume ratio 1:2 solvent elution fraction), Fr-3(9.3g, chloroform elution fraction), Fr-4(2.1g, chloroform elution fraction), Fr-5(1.6g, chloroform-methanol volume ratio 99:1 solvent elution fraction), Fr-6(2.1g, chloroform-methanol volume ratio 99:1 solvent elution fraction), Fr-7(0.6g, chloroform-methanol volume ratio 98:2 solvent elution fraction), Fr-8(6.2g, chloroform-methanol volume ratio 97:3 solvent elution fraction), Fr-9(3.6g, chloroform-methanol volume ratio 95:5 solvent elution fraction), Fr-10(2.7g, chloroform-methanol volume ratio 93:7 solvent elution fraction), and chloroform-methanol elution fraction, Fr-11(2.6g, chloroform-methanol volume ratio 9:1 solvent elution component), Fr-12(3.0g, chloroform-methanol volume ratio 8:2 solvent elution component), Fr-13 (methanol elution component). Wherein 9 components Fr-1, Fr-2, Fr-3, Fr-5, Fr-6, Fr-7, Fr-8, Fr-9 and Fr-10 show strong antitumor activity, and the inhibition rates of the components on K562 cells at a concentration of 100 mu g/ml are respectively 45.7%, 41.9%, 91.0%, 54.9%, 90.7%, 78.9%, 48.6%, 54.5% and 46.1%. The results of analysis by thin layer chromatography showed that one of the components Fr-6 contained the target compounds 1 and 2.
Fr-6(2.1g) is dissolved by using a proper amount of 95% (v/v) ethanol, wet loading is carried out, the obtained solution is added to a SephadexLH-20 column (column bed: 4.5cm multiplied by 50 cm) pre-loaded with 95% (v/v) ethanol, elution separation is carried out by using 95% (v/v) ethanol as an eluent, eluent is collected according to the detection result of silica gel thin layer chromatography, and is combined and concentrated, and 9 components are sequentially obtained according to the elution order: fr-6-1(30mg), Fr-6-2(45mg), Fr-6-3(85mg), Fr-6-4(300mg), Fr-6-5(460mg), Fr-6-6(236mg), Fr-6-7(280mg), Fr-6-8(210mg), and Fr-6-9(440 mg). Wherein Fr-6-4(300mg) is a target component containing the compounds 1 and 2, and has an inhibition rate of 51.9% on K562 cells at a concentration of 100. mu.g/mL. Dissolving Fr-6-4(300mg) in appropriate amount of mixed solvent of chloroform-methanol at volume ratio of 1:1, wet loading, adding into SephadexLH-20 column (bed: 1.5 cm. times.80 cm) pre-packed in mixed solvent of chloroform-methanol at volume ratio of 1:1, eluting with mixed solvent of chloroform-methanol at volume ratio of 1:1 as eluent, collecting eluates containing compounds 1 and 2, mixing, and concentrating to obtain column chromatography component A (190 mg) containing target compounds 1 and 2.
4. Isolation preparation of Compounds 1 and 2
Column chromatography fraction a (190 mg) containing compounds 1 and 2 was dissolved in an appropriate amount of methanol, filtered through a 0.22 μm filter membrane, subjected to preparative reverse phase HPLC separation using a Waters600 high performance liquid chromatograph (Waters 600 controller, Waters600 pump, Waters2998PDA detector, Empower chromatography workstation) (HPLC column: CapcellPakC18,20mm × 250mm, column temperature room temperature, mobile phase methanol-water volume fraction 80:20, flow rate 10ml/min, detection wavelength 210nm, collecting retention time (t)R) Corresponding eluates of two elution peaks at 29.9min and 66.2min gave HPLC component B1 containing Compound 1 as the major component (tR=29.9 min) and HPLC component B2 (t) containing compound 2 as the main componentR=66.2min)。
The HPLC fractions B1 obtained were all dissolved in an appropriate amount of methanol, filtered through a 0.22 μm filter and subjected to semi-preparative reversed-phase HPLC separation using a Waters600 high performance liquid chromatograph (Waters 600 controller, Waters600 pump, Waters2998PDA detector, Empower chromatography workstation) (HPLC column: CapcellPakC18,10mm × 250mm, column temperature room temperature, mobile phase methanol-water volume fraction 86:14, flow rate 3ml/min, detection wavelength 210nm, and refining to obtain pure compound 1 13mg (retention time t)R=43.7min)。
The HPLC fractions B2 were all dissolved in the appropriate amount of methanol, filtered through a 0.22 μm filter and subjected to semi-preparative reversed-phase HPLC separation using a Waters600 high performance liquid chromatograph (Waters 600 controller, Waters600 pump, Waters2998PDA detector, Empower chromatography workstation) (HPLC column: CapcellPak C18,10mm × 250mm, column temperature room temperature, mobile phase methanol-water volume fraction 82:18, flow rate 3ml/min, detection wavelength 210 nm), and refining to obtain pure compound 2 5.5mg (retention time t)R=37.0min)。
In addition, through the experimental operation of the 50-140L scale of the steps 1 to 4, which are repeatedly carried out for another plurality of times, 350mg of the pure compound 1 and 170mg of the pure compound 2 are obtained in an additional accumulation mode.
5. Physicochemical constants and Popp data for Compounds 1 and 2
Compound 1, white crystalline solid (methanol), mp 131-132 deg.C, is easily soluble in chloroform, soluble in methanol, ethanol, acetone, insoluble in water,99.7(c0.5, methanol). Positive ion ESI-MSm/z 863[ M + H ]]+,885[M+Na]+,901[M+K]+Negative ion ESI-MSm/z 861[ M-H ]]-,897[M+Cl]-,907[M+HCOO]-. Positive ion HR-ESI-MSm/z, found 863.4969[ M + H [ ]]+Calculated value 863.4959 (C)51H67N4O8[M+H]+) Measured value of 885.4780[ M + Na ]]+Calculated value 885.4778 (C)51H66N4O8Na[M+Na]+) Measured value of 901.4518[ M + K]+Calculated value 901.4518 (C)51H66N4O8K[M+K]+)。UVλmaxnm(log)inMeOH:298(3.47),244(4.10),209(4.69)。IRνmaxcm-1:3292,3080,2933,2873,1667,1607,1528,1489,1454,1380,1365,1335,1304,1273,1200,1106,1077,1058,1032,983,931,895,862,815,748,703。CDλmaxnm(mdeg)inMeOHat200μg/ml:195.5(-8.37),205.2(0),208.5(+2.04),210.2(0),215.5(-12.86),225.6(0),232.0(+2.54),237.0(0),249.5(-13.62),315.1(0),319.0(+0.31),320.0(+0.32),321.5(+0.30),328.5(+0.40),330.0(+0.42),331.5(+0.38),340.0(+0.47),344.0(+0.50),351.0(+0.54),358.0(+0.22),359.0(+0.31),361.5(+0.29),367.5(+0.37),369.0(+0.37),371.5(+0.32),374.5(+0.37),375.5(+0.37),381.5(+0.18),387.5(+0.44),390.9(0),394.0(+0.09),398.0(+0.13),399.9(0)。600MHz1H and 150MHz13CNMR data: see table 1. NMR data of Compound 1 shown in Table 1 based thereon1H spectrum,13One-dimensional spectra such as C full decoupling spectrum, DEPT spectrum, NOE difference spectrum, etc., and1H-1and attributing two-dimensional map analysis results of HCOSY, HMQC, HMBC, ROESY and the like.
Compound 2, yellowish crystalline solid (methanol), mp 125-126 deg.C, is easily soluble in chloroform, soluble in methanol, ethanol, acetone, insoluble in water,65.8(c0.2, methanol). Positive ion ESI-MSm/z 879[ M + H ]]+877[ M-H ] negative ion ESI-MSm/z]-,913[M+Cl]-. Positive ion HR-ESI-MSm/z, found 879.4902[ M + H [ ]]+Calculated value 879.4908 (C)51H67N4O9[M+H]+) Measured value of 901.4724[ M + Na ]]+Calculated value 901.4728 (C)51H66N4O9Na[M+Na]+) Measured value of 917.4456[ M + K]+Calculated value 917.4467 (C)51H66N4O9K[M+K]+)。UVλmaxnm(log)inMeOH:297(3.42),209(4.64)。IRνmaxcm-1:3291,2937,2874,1667,1519,1489,1450,1379,1367,1335,1304,1272,1242,1204,1177,1112,1058,1033,984,933,896,862,751。CDλmaxnm(mdeg)inMeOHat200μg/ml:196.5(-12.05),202.3(0),207.0(+4.55),211.3(0),216.0(-8.15),232.6(0),235.5(+0.65),238.1(0),251.5(-8.29),273.7(0),282.5(+0.42),290.0(+0.18),297.5(+0.25),301.6(0),318.5(+0.45),322.0(+0.34),324.5(+0.37),328.5(+0.53),329.5(+0.54),330.5(+0.55),331.5(+0.56),339.5(+0.60),344.0(+0.59),346.5(+0.57),351.0(+0.63),360.5(+0.48),361.5(+0.49),366.5(+0.41),368.5(+0.45),376.5(+0.32),377.5(+0.31),387.5(+0.39),394.0(+0.14),396.5(+0.11),399.1(0)。600MHz1H and 150MHz13CNMR data: see table 1. NMR data of Compound 2 shown in Table 1 based thereon1H spectrum,13One-dimensional spectra such as C full decoupling spectrum, DEPT spectrum, NOE difference spectrum, etc., and1H-1and attributing two-dimensional map analysis results of HCOSY, HMQC, HMBC, ROESY and the like.
TABLE 1 Compounds 1 and 2 in CDCl3600MHz of1H and 150MHz13CNMR data
Example 2: fermentation culture of penicillium purpurogenum3-f-31 and separation preparation of compound 1
1. Fermentation culture and extraction treatment of fermented product
1) Production strain
The strain for producing compound 1 by fermentation in this example is Penicillium purpurogenum3-f-31, deposited in the general microbiological center of the China Committee for culture Collection of microorganisms, with the accession number 7286 (CGMCC No. 7286).
2) Fermentation culture
A test tube slant is prepared from PDA culture medium (composed of glucose 2%, agar 2%, and NaCl1.5% and prepared from 20% potato decoction) of Penicillium purpurogenum3-f-31 stored in a refrigerator at 4 deg.C, an inoculating loop is used to scrape appropriate amount of spores under aseptic condition, and the spore is streaked and inoculated onto newly prepared PDA solid culture medium plate, and cultured in an incubator at 28 deg.C for 3-5 days. And (3) scraping a proper amount of fresh spores by using an inoculating ring after the spores are formed, putting the fresh spores into a 50ml conical flask filled with a proper amount of sterile water and glass beads, and fully shaking the conical flask to ensure that the glass beads are rotated and beaten to uniformly disperse the spores to obtain a crude spore suspension. Taking 200 mu l of the crude spore suspension, placing the crude spore suspension in a 96-well plate, measuring the OD value under 600nm by using an enzyme-labeling instrument, diluting the crude spore suspension under the detection of the OD value until the OD value reaches 0.5, and recording the dilution times. Accordingly, the whole crude spore suspension was diluted with sterile water by the same factor to prepare a spore suspension of 3-f-31 for inoculation. The spore suspension was inoculated into 120 500ml Erlenmeyer flasks each containing 240ml of a liquid fermentation medium (composition: glucose 2%, maltose 1%, mannitol 2%, glutamic acid 1%, peptone 0.5%, yeast extract powder 0.3%) at an inoculation amount of 140. mu.l per flask, and subjected to shake culture at 28 ℃ and 180rpm for 10 days to obtain about 28.8L of a fermentation broth.
2. Extraction treatment and preparation of ethyl acetate extract
About 28.8L of the total fermentation broth was filtered through 4 layers of gauze to separate the filtrate and the biomass. Extracting the filtrate with equal volume of ethyl acetate for 4 times, mixing the obtained ethyl acetate extractive solutions, and concentrating under reduced pressure to obtain ethyl acetate extract of the filtrate. Adding acetone twice the volume of the thallus to make the volume percentage of the acetone reach about 67 percent, fully stirring and suspending, carrying out ultrasonic treatment for 5 hours to break the thallus, filtering by using 4 layers of gauze, and filtering to obtain an aqueous acetone extracting solution. The same extraction of the cells was repeated for a total of 4 times, and the resulting aqueous acetone extracts were combined and concentrated under reduced pressure until acetone was not contained. About 4L of the residual aqueous layer was extracted 5 times with an equal volume of ethyl acetate, and the resulting ethyl acetate extracts were combined and concentrated under reduced pressure to give an ethyl acetate extract of the cells. Silica gel thin layer chromatography detection results show that the product spots contained in the filtrate and the ethyl acetate extract of the thalli are basically the same, so the two extracts are combined and then are concentrated to be dry under reduced pressure to obtain 29.9g of ethyl acetate total extract. The extract has 78% inhibition rate on K562 cells at 100 μ g/ml concentration.
3. Separation of ethyl acetate extract and preparation of column chromatography component containing target compound
29.9g of the above ethyl acetate total extract was sufficiently dissolved in a large amount of methanol, and then filtered, concentrated and dried to separate into 6.5g of methanol-insoluble matter and 23.4g of methanol-soluble matter. Wherein, the methanol insoluble substance is mainly a mucoid substance and a part of solid matters remained after cell membrane disruption, has no inhibition effect on K562 cells, while the methanol soluble substance has strong inhibition effect on the K562 cells, and the inhibition rate on the K562 cells under the concentration of 100 mu g/ml is as high as 82.4%.
Dissolving 23.4g of the methanol soluble substance by using a proper amount of mixed solvent with a dichloromethane-methanol volume ratio of 1:2, adding 60g of silica gel (100-. Collecting 75 fractions of eluent per 500ml, mixing corresponding fractions according to the detection result of silica gel thin layer chromatography, and concentrating under reduced pressure to dry to obtain 14 components: fr-1(0.11g, petroleum ether elution component), Fr-2(1.90g, dichloromethane elution component), Fr-3(1.50g, dichloromethane-methanol volume ratio 99:1 solvent elution component), Fr-4(5.45g, dichloromethane-methanol volume ratio 99:1 → 98:2 solvent elution component), Fr-5(7.28g, dichloromethane-methanol volume ratio 98:2 → 97:3 solvent elution component), Fr-6(0.99g, dichloromethane-methanol volume ratio 97:3 → 96:4 solvent elution component), Fr-7(0.90g, dichloromethane-methanol volume ratio 96:4 → 95:5 → 92:8 solvent elution component), Fr-8(0.41g, dichloromethane-methanol volume ratio 92:8 → 9:1 solvent elution component), Fr-9(0.66g, dichloromethane-methanol volume ratio 9:1 → 17:3 solvent elution component), Fr-10(0.69g, dichloromethane-methanol volume ratio 17:3 → 12:3 → 7:3 solvent elution component), Fr-11(0.87g, dichloromethane-methanol volume ratio 7:3 → 1:1 solvent elution component), Fr-12(1.05g, acetone → methanol elution component), Fr-13(0.05g, methanol elution component), Fr-14(1.10g, methanol elution component). Wherein 8 components Fr-3, Fr-4, Fr-5, Fr-6, Fr-7, Fr-8, Fr-9, Fr-10, Fr-11 and Fr-12 show different degrees of antitumor activity, and the inhibition rates of K562 cells at a concentration of 100. mu.g/ml are 30.4%, 67.6%, 73.2%, 58.1%, 58.8%, 26.1%, 54.1%, 54.0%, 43.3% and 31.1%, respectively. The results of analysis by thin layer chromatography showed that one of the components Fr-5 contained the target compound 1.
Fr-5(7.28 g) is dissolved by a proper amount of methanol, wet loading is carried out, the obtained product is added to a SephadexLH-20 column (column bed: 5cm multiplied by 43 cm) pre-filled in 95% (v/v) ethanol, elution and chromatographic separation are carried out by using 95% (v/v) ethanol as an eluent, eluent is collected according to a thin-layer detection result, and is combined and concentrated, and 11 components are sequentially obtained according to the elution order: fr-5-1(600mg), Fr-5-2(2.75g), Fr-5-3(180mg), Fr-5-4(1.7g), Fr-5-5(170mg), Fr-5-6(70mg), Fr-5-7(28mg), Fr-5-8(1.5g), Fr-5-9(130mg), Fr-5-10(15mg), Fr-5-11(10 mg). The inhibition rates of the components on K562 cells at the concentration of 100 mu g/ml are 67.2%, 80.2%, 77.4%, 51.1%, 14.8%, 16.8%, 14.4%, 25.3%, 62.2%, 63.5% and 75.5%, respectively, which shows that 7 components, such as Fr-5-1 to Fr-5-4 and Fr-5-9 to Fr-5-11, are active components with stronger antitumor effect. Wherein Fr-5-1 is a target component containing the compound 1. Fr-5-1(600mg) was dissolved in an appropriate amount of methanol, and then 2g of reversed-phase silicA gel ODS (YMC. about. GELODS-A-HG, 12 nmS-50 μm, AAG12S 50) was added to the resulting solution, and the resulting solution was uniformly mixed, dried and ground, and then applied to A vacuum glass column (column bed: 2.5 cm. times.20 cm) containing 10g of the same reversed-phase silicA gel ODS, and the column chromatography was carried out using A water-methanol-acetone mixed solvent system as an eluent, by sequentially increasing the volume fraction of methanol or acetone in the eluent to decrease the polarity, thereby carrying out gradient elution column chromatography. Collecting and combining corresponding eluent fractions according to a thin-layer chromatography detection result, and respectively concentrating and drying to obtain 7 components: fr-5-1-1(200mg, water-methanol volume ratio 4:1 → 1:4 solvent elution fraction), Fr-5-1-2(14.3mg, water-methanol volume ratio 1:4 solvent elution fraction), Fr-5-1-3(16mg, water-methanol volume ratio 3:17 solvent elution fraction), Fr-5-1-4(50mg, water-methanol volume ratio 1:9 solvent elution fraction), fr-5-1-5(35mg, water-methanol volume ratio 1:9 → 1:19 solvent elution fraction), Fr-5-1-6(130mg, water-methanol volume ratio 1:19 → methanol elution fraction), Fr-5-1-7(80mg, methanol → methanol-acetone volume ratio 1:1 solvent elution fraction). The inhibition rates of the components on K562 cells at the concentration of 100 mu g/ml are respectively 56.7%, 90.4%, 91.4%, 65.6%, 48.4%, 8.6% and 9.1%, which indicates that Fr-5-1-1, Fr-5-1-2, Fr-5-1-3, Fr-5-1-4 and Fr-5-1-5 are active components with stronger antitumor effect. The detection result of the thin layer chromatography shows that Fr-5-1-3 is a column chromatography component containing the compound 1.
4. HPLC separation preparation of Compound 1
Column chromatography component Fr-5-1-3(16 mg) containing compound 1 was dissolved in an appropriate amount of methanol, filtered through a 0.22 μm filter membrane, subjected to preparative reverse phase HPLC separation using a Waters600 high performance liquid chromatograph (Waters 600 controller, Waters600 pump, Waters2998PDA detector, Empower chromatography workstation) (HPLC column: CapcellPakC18,column (20 mm × 250 mm), column temperature (room temperature), mobile phase (methanol-water volume fraction: 81: 19), flow rate: 6ml/min, detection wavelength: 210 nm), and refining to obtain compound 1 (retention time t)R=106.0 min) pure product 5.1 mg.
In addition, 65mg of the pure compound 1 is obtained by additionally accumulating the experimental operation of the steps 1 to 4 on the scale of 40-120L.
Example 3: derivatization preparation of other inventive compounds 1 a-1I and 2 a-2 r of the formula I
1) Derivatization preparation of Compounds 1 a-1I of the formula I according to the invention
Approximately 10mg of the compound 1 obtained in example 1 or example 2 was weighed, dissolved in 0.5ml of acetone, and 50mg of anhydrous K was added2CO2Mixing, adding dropwise 50 μ l of methyl iodide under magnetic stirring at 60 deg.C for methylationAnd reacting for 6 h. The reaction product was separated and purified by preparative silica gel thin layer chromatography (chloroform-methanol volume ratio 93:7 development) to obtain 1a (1.3 mg, positive ion ESI-MSm/z:877[ M + H ] except that 5mg of the starting compound 1 was recovered]+Negative ion ESI-MSm/z:875[ M-H ]]-)。
Approximately 10mg of the compound 1 obtained in example 1 or example 2 was weighed, dissolved in 0.5ml of acetone, and 50mg of anhydrous K was added2CO2Mixing, and adding 50 μ l diethyl sulfate dropwise under magnetic stirring at 60 deg.C for ethylation reaction for 6 hr. The reaction product was separated and purified by preparative silica gel thin layer chromatography (chloroform-methanol volume ratio 93:7 development) to obtain 1b (1.2 mg, positive ion ESI-MSm/z:891[ M + H ] except that 5mg of the starting compound 1 was recovered]+,ESI-MSm/z:889[M-H]-)。
Approximately 10mg of the compound 1 prepared in the above examples 1 and 2 was weighed, dissolved in 0.25ml of anhydrous pyridine, rapidly added with 0.25ml of acetic anhydride, mixed well, and left to stand at room temperature for 24 hours in the dark for acetylation. Separating and purifying the reaction product by preparative silica gel thin layer chromatography (chloroform-methanol volume ratio 92:8 development) to obtain 1c (3 mg, positive ion ESI-MSm/z:905[ M + H ]]+Negative ion ESI-MSm/z:903[ M-H ]]-)。
About 10mg of the compound 1 prepared in example 1 and example 2 was weighed, dissolved in 0.25ml of acetone, mixed with 0.25ml of a 10mg/ml acetone solution of gallic acid, and then mixed with 1 drop of 6N hydrochloric acid, followed by acylation reaction for 7 days while keeping out of the sun at room temperature. The reaction product was separated and purified by preparative silica gel thin layer chromatography (chloroform-methanol volume ratio 80:20 development) to obtain 1d (0.9 mg, positive ion ESI-MSm/z:1015[ M + H ] in addition to 7mg of the starting compound 1]+(ii) a Negative ion ESI-MSm/z 1013[ M-H]-)。
About 10mg of the compound 1 prepared in example 1 and example 2 was weighed, dissolved in 0.2ml of anhydrous pyridine, rapidly added with 16mg of tribenzylgalloyl chloride, mixed and dissolved, and left at 50 ℃ in the dark for 48 hours to carry out acylation reaction. The reaction product was separated by preparative silica gel thin layer chromatography (chloroform-methanol volume ratio 95:5 development)Purifying to obtain 1e (2 mg, positive ion ESI-MSm/z:1285[ M + H ]]+(ii) a Negative ion ESI-MSm/z 1283[ M-H ]]-)。
About 10mg of the compound 1 prepared in example 1 and example 2 was weighed, dissolved in 0.2ml of anhydrous pyridine, rapidly mixed with 10. mu.l of benzoyl chloride, and left to stand at room temperature in the dark for acylation reaction for 24 hours. Separating and purifying the reaction product by preparative silica gel thin layer chromatography (chloroform-methanol volume ratio 93:7 development) to obtain 1f (2.8 mg, positive ion ESI-MSm/z:967[ M + H ]]+(ii) a Negative ion ESI-MSm/z:965[ M-H ]]-)。
About 10mg of the compound 1 prepared in example 1 and example 2 was weighed, dissolved in 0.2ml of anhydrous pyridine, rapidly added with 13mg of p-nitrobenzoyl chloride, mixed well, and left to stand at room temperature in the dark for acylation reaction for 10 hours. The reaction product was separated and purified by preparative silica gel thin layer chromatography (chloroform-methanol volume ratio 91:9 development) to give 1g (3.1mg, positive ion ESI-MSm/z:1012[ M + H ]]+(ii) a Negative ion ESI-MSm/z 1010[ M-H ]]-)。
About 10mg of the compound 1 prepared in example 1 and example 2 was weighed, dissolved in 0.2ml of anhydrous pyridine, quickly added with 10. mu.l of p-chlorobenzoyl chloride, mixed well, and left to stand at room temperature in the dark for acylation reaction for 10 hours. Separating and purifying the reaction product by preparative silica gel thin layer chromatography (chloroform-methanol volume ratio 92:8 development) to obtain 1H (3 mg, positive ion ESI-MSm/z:1001[ M + H ]]+(ii) a Negative ion ESI-MSm/z 999[ M-H [ ]]-)。
About 10mg of the compound 1 prepared in example 1 and example 2 was weighed, dissolved in 0.2ml of anhydrous pyridine, rapidly added with 8. mu.l of p-fluorobenzoyl chloride, mixed well, and left to stand at room temperature in the dark for acylation reaction for 10 hours. Separating and purifying the reaction product by preparative silica gel thin layer chromatography (chloroform-methanol volume ratio 92:8 development) to obtain 1i (2.5 mg, positive ion ESI-MSm/z:985[ M + H ]]+(ii) a Negative ion ESI-MSm/z 983[ M-H ]]-)。
2) Derivatization preparation of the compounds 2 a-2 r of the formula I according to the invention
Weighing the product obtained in example 1About 10mg of Compound 2 was dissolved in 0.5ml of acetone, and 50mg of anhydrous K was added2CO2Shaking up, and dripping 50 mul of methyl iodide under magnetic stirring at 60 ℃ to carry out methylation reaction for 6 h. The reaction product was separated and purified by preparative silica gel thin layer chromatography (chloroform-methanol volume ratio 93:7 development) to obtain 2a (2.1 mg, positive ion ESI-MSm/z:893[ M + H ] except that 6mg of the starting compound 2 was recovered]+Negative ion ESI-MSm/z 891[ M-H ]]-) And 2b (1.3 mg, positive ion ESI-MSm/z:907[ M + H ]]+,ESI-MSm/z:905[M-H]-)。
Approximately 10mg of the compound 2 prepared in example 1 above was weighed, dissolved in 0.5ml of acetone, and 50mg of anhydrous K was added2CO2Shaking up, and dropwise adding 50 mul diethyl sulfate under magnetic stirring at 60 ℃ to carry out ethylation reaction for 6 h. The reaction product was separated and purified by preparative silica gel thin layer chromatography (chloroform-methanol volume ratio 93:7 development) to obtain 2c (2.3 mg, positive ion ESI-MSm/z:907[ M + H ] in addition to 5mg of the starting compound 2]+Negative ion ESI-MSm/z 905[ M-H ]]-) And 2d (1.5 mg, positive ion ESI-MSm/z:935[ M + H ]]+,ESI-MSm/z:933[M-H]-)。
About 10mg of the compound 2 prepared in example 1 was weighed, dissolved in 0.25ml of anhydrous pyridine, quickly added with 0.25ml of acetic anhydride, mixed well, and left to stand at room temperature for 24 hours in the dark for acetylation. Separating and purifying the reaction product by preparative silica gel thin layer chromatography (chloroform-methanol volume ratio 92:8 development) to obtain 2e (2.5 mg, positive ion ESI-MSm/z:921[ M + H ]]+Negative ion ESI-MSm/z 919[ M-H ]]-) And 2f (1.4 mg, positive ion ESI-MSm/z:963[ M + H ]]+Anion ESI-MSm/z:961[ M-H ]]-)。
About 10mg of the compound 2 prepared in example 1 was weighed, dissolved in 0.25ml of acetone, dissolved in 4mg of gallic acid, mixed and dissolved, added dropwise with 1 drop of 6N hydrochloric acid and shaken, and left to stand in the dark at room temperature for acylation reaction for 7 days. The reaction product was separated and purified by preparative silica gel thin layer chromatography (chloroform-methanol volume ratio 80:20 development) to obtain 2g (1.1 mg, positive ion ESI-MSm/z:1031[ M + H ] in addition to recovering 4mg of starting compound 2]+(ii) a Negative ion ESI-MSm/z 1029[ M-H ]]-) And 2H (0.9 mg, positive ion ESI-MSm/z:1183[ M + H ]]+(ii) a Negative ion ESI-MSm/z 1181[ M-H ]]-)。
Weighing about 10mg of the compound 2 prepared in the example 1, adding 0.2ml of anhydrous pyridine for dissolving, quickly adding 16mg of tribenzylgalloyl chloride for uniformly mixing and dissolving, and standing for 48 hours at 40 ℃ in the dark for acylation reaction. The reaction product was separated and purified by preparative silica gel thin layer chromatography (chloroform-methanol volume ratio 95:5 developed) to give 2i (3 mg, positive ion ESI-MSm/z:1301[ M + H ])]+(ii) a Negative ion ESI-MSm/z 1299[ M-H ]]-) And 2j (1.5 mg, positive ion ESI-MSm/z:1723[ M + H ]]+(ii) a Negative ion ESI-MSm/z 1721M-H]-)。
About 10mg of the compound 2 prepared in example 1 was weighed, dissolved in 0.2ml of anhydrous pyridine, quickly mixed with 5. mu.l of benzoyl chloride, and left to stand at room temperature in the dark for acylation reaction for 24 hours. Separating and purifying the reaction product by preparative silica gel thin layer chromatography (chloroform-methanol volume ratio 93:7 development) to obtain 2k (2 mg, positive ion ESI-MSm/z:983[ M + H ]]+(ii) a Negative ion ESI-MSm/z 981[ M-H ]]-) And 2l (1.7 mg, positive ion ESI-MSm/z:1087[ M + H ]]+(ii) a Negative ion ESI-MSm/z 1085[ M-H ]]-)。
About 10mg of the compound 2 prepared in example 1 was weighed, dissolved in 0.2ml of anhydrous pyridine, rapidly added with 13mg of p-nitrobenzoyl chloride, mixed and dissolved, and left to stand away from light for acylation reaction at room temperature for 10 hours. Separating and purifying the reaction product by preparative silica gel thin layer chromatography (chloroform-methanol volume ratio 91:9 development) to obtain 2M (2 mg, positive ion ESI-MSm/z:1028[ M + H ])]+(ii) a Negative ion ESI-MSm/z 1026[ M-H ]]-) And 2n (1.6 mg, positive ion ESI-MSm/z:1177[ M + H)]+(ii) a Negative ion ESI-MSm/z 1175[ M-H ]]-)。
About 10mg of the compound 2 prepared in example 1 was weighed, dissolved in 0.2ml of anhydrous pyridine, and then mixed with 6. mu.l of p-chlorobenzoyl chloride quickly, and left to stand in the dark at room temperature for acylation reaction for 10 hours. Separating and purifying the reaction product by preparative silica gel thin layer chromatography (chloroform-methanol volume ratio 91:9 development)To obtain 2o (2.1 mg, positive ion ESI-MSm/z:1017[ M + H ]]+(ii) a Negative ion ESI-MSm/z 1015[ M-H ]]-) And 2p (1.9 mg, positive ion ESI-MSm/z:1155[ M + H ]]+(ii) a Negative ion ESI-MSm/z 1153[ M-H ]]-)。
About 10mg of the compound 2 prepared in example 1 was weighed, dissolved in 0.2ml of anhydrous pyridine, and then mixed with 6. mu.l of p-fluorobenzoyl chloride quickly, and left to stand at room temperature in the dark for acylation reaction for 10 hours. Separating and purifying the reaction product by preparative silica gel thin layer chromatography (chloroform-methanol volume ratio 91:9 development) to obtain 2q (2.3 mg, positive ion ESI-MSm/z:1001[ M + H ]]+(ii) a Negative ion ESI-MSm/z 999[ M-H [ ]]-) And 2r (1.9 mg, positive ion ESI-MSm/z:1123[ M + H ]]+(ii) a Negative ion ESI-MSm/z 1121[ M-H ]]-)。
Example 4: test of the antitumor Activity of the Compounds of the formula I according to the invention
1. Experimental Material
1) Preparation of solution of sample to be tested
The test samples were compound 1, compound 2 isolated as described in examples 1 and 2 above, and other compounds 1 a-1I and 2 a-2 r of formula I of the present invention derivatized as described in example 3 above. Wherein, the compound 1 and 2 are firstly prepared into mother liquor of 10.0mg/ml by methanol, and then are prepared into methanol solutions of 10.0, 5.0, 2.5, 1.25, 0.625, 0.3125, 0.1562 and 0.0781mg/ml series concentration by dilution by multiple ratio to test the activity, while the compound 1 a-1 i and the compound 2 a-2 r are only prepared into methanol solutions of 2.5mg/ml single concentration to test the activity. A10.0 mg/ml methanol solution of 5-fluorouracil (Aladdin reagent Co., Ltd., lot No. 5402) was used as a positive control, and methanol was used as a blank control.
2) Cell line and subculture of cells
The activity test was carried out using a human chronic myelogenous leukemia K562 cell line, a human acute promyelocytic leukemia HL-60 cell line, a human cervical cancer HeLa cell line, a human gastric cancer BGC-823 cell line, and a human breast cancer MCF-7 cell line (all of which are commercially available, for example, from Yaji Biotech, Inc., Shanghai Smart laboratory facilities, Inc., McMessah, Inc., Shanghai).
K562, HL-60, HeLa, BGC-823 and MCF-7 cells were passaged routinely in RPMI-1640 medium containing 10% fetal bovine serum and 100. mu.g/ml each of penicillin and streptomycin, and maintained in a cell culture chamber with 5% carbon dioxide at 37 ℃.
2. Activity test method
The antitumor activity of the sample is tested by adopting an MTT method and a cell morphology detection method, and K562, HL-60, HeLa, BGC-823 and MCF-7 cells in a logarithmic growth phase are respectively prepared into cells with the cell density of 2 × 10 by using a fresh RPMI-1640 culture medium4Cell suspension of one/ml, seeded in 96-well plates at 200. mu.l per well. After inoculation, suspension cells K562 and HL-60 were cultured at 37 ℃ for 2h, while adherent cells HeLa, BGC-823 and MCF-7 were cultured at 37 ℃ for 12 h. Thereafter, 2. mu.l of the drug sample solution was added to each well of the sample group, and 2. mu.l of methanol was added to each well of the blank control group, and the incubation was continued at 37 ℃ for 24 hours. And after the culture is finished, observing the morphological change of the tested cells under an optical microscope, observing the morphological characteristics of the presence or absence of typical abnormal cells, apoptotic cells or necrotic cells, and according to the morphological change condition of the tested cells, performing direct comparison and control with a blank control group to preliminarily judge whether the anti-tumor activity of the sample on the tested cells exists or not, and taking a picture if necessary. Thereafter, 20. mu.l of a precooled 5mg/ml MTT solution (prepared in PBS) was added to each well, incubated at 37 ℃ for 4 hours, centrifuged at 4 ℃ and 2000rpm for 10 minutes, the supernatant was aspirated, 150. mu.l of DMSO was added to each well, the resulting mixture was placed on a microplate reader and sufficiently shaken to completely dissolve the MTT purple product, and the OD at 570nm was measured in each well. In the experiment, three parallel holes are respectively arranged on a sample and a blank control group, the average value of three holes OD is taken, and the formula IR% = (OD) is adoptedBlank space-ODSample (I))/ODBlank space× 100%, the inhibition rate (IR%) of the sample on the test cancer cells was calculated, half the Inhibitory Concentration (IC) of compounds 1 and 2 on the test cancer cells50) According to differentThe inhibition rate at concentration was calculated.
3. Results of the experiment
1) MTT method test results
In the MTT method test, the compounds 1 and 2 showed strong antitumor activity for inhibiting cell proliferation on tested K562, HL-60, HeLa, BGC-823 and MCF-7 cells, and IC of the compounds on the 5 tested cells50The results of the value measurement are shown in table 2 below.
TABLE 2 IC inhibition of human cancer cell proliferation by Compounds 1 and 250Measurement of value (. mu.M)
The compounds 1 a-1 i and 2 a-2 r also show strong antitumor activity for inhibiting cell proliferation on tested K562, HL-60, HeLa, BGC-823 and MCF-7 cells, and the inhibition rates of the compounds on the cells are all over 40% under the concentration of 25 mu g/ml and are respectively distributed in the interval of 40% -87%.
In the experiment, the inhibition rates of positive control 5-fluorouracil on tested K562, HL-60, HeLa, BGC-823 and MCF-7 cells at the concentration of 100 mu g/ml are 39.3%, 54.2%, 55.5%, 49.6% and 43.2% respectively.
These results indicate that the compounds of the present invention have superior antitumor activity against the above cancer cells in vitro than 5-fluorouracil.
2) Results of cell morphology examination
When the tested cells are treated by the compounds 1 and 2 with the series of concentrations of 100 mu g/ml-0.781 mu g/ml for 24 hours under an optical inverted microscope, part of the cells in the visual field are in the typical shapes of necrotic cells such as cell expansion and cytoplasm agglutination, part of the cells are in the morphological characteristics of apoptotic cells such as snowflake or fragments which are not completely scattered, and part of the cells are in heterotypic shapes such as short thick rods, fusiform or bigement shapes which do not complete cell division: the necrotic morphological cells in the visual field of the high-concentration treatment group of 100 mug/ml are abundant, but as the concentration is reduced, the necrotic cells in the visual field are gradually reduced, and the apoptotic morphological cells and the heterotypic morphological cells are gradually increased and are also gradually increased along with the normal morphological cells; the number of normal morphology cells increased progressively and markedly as the concentration decreased to and further below 3.125. mu.g/ml. The morphological detection results show that the compounds 1 and 2 exert the antitumor effect of inhibiting the proliferation of cancer cells through various ways such as killing cytotoxicity to tested tumor cells, inducing the tested cells to generate apoptosis, acting on skeleton protein to inhibit the division of the tested cells and the like.
In addition, it was observed under an optical inverted microscope that after the cancer cells were treated with 25. mu.g/ml of each of the compounds 1 a-1 i and 2 a-2 r for 24 hours, many of the cells in the field exhibited typical morphology of necrotic cells such as enlarged cell bodies and aggregated cell cytoplasm, and some of the cells exhibited morphological characteristics of apoptotic cells such as snowflake-like or not yet completely scattered flakes, and some of the cells exhibited abnormal morphology such as short thick rods, spindle-like or bigeminal, in which intact cells were not completely divided, while the number of cells exhibiting normal morphology was relatively small in the field. These morphological results show that, like compounds 1 and 2, compounds 1 a-1 i and 2 a-2 r exert their antitumor effects of inhibiting cancer cell proliferation by various pathways such as cytotoxic activity against cancer cells to be tested, induction of apoptosis in test cells, and inhibition of division of test cells by acting on a skeletal protein.
4. Conclusion
The compound of the formula I has strong antitumor activity, and exerts the antitumor effect of inhibiting the proliferation of cancer cells through the ways of killing cytotoxicity to the cancer cells to be tested, inducing the apoptosis of the cancer cells to be tested, acting on a skeleton protein to inhibit the division of the cancer cells to be tested and the like. Therefore, the compound of the formula I can be used as a cytoskeletal protein inhibitor, an apoptosis inducer, a tumor cell proliferation inhibitor or a tumor cell killing agent, and can also be used as an anti-tumor medicament for treating tumors.
Although specific embodiments of the invention have been described in detail, it will be appreciated by those skilled in the art that, based upon the overall teachings of the disclosure, various modifications and alternatives to those details could be developed and still be encompassed by the present invention. The full scope of the invention is given by the appended claims and any equivalents thereof.
Claims (35)
1. A compound of formula I, or a pharmaceutically acceptable salt thereof,
wherein,
R1represents substituted or unsubstituted C1-10A linear or branched alkyl group;
R2and R3Each independently represents hydrogen, hydroxy, substituted or unsubstituted:
C1-10straight or branched alkoxy, C2-8Straight chain or branched chain saturated aliphatic acyloxy or aromatic acyloxy,
the substituent is selected from hydroxyl, halogen, nitro and benzyloxy, and the number of the substituent is 1, 2 or 3.
2. A compound of formula I according to claim 1, or a pharmaceutically acceptable salt thereof, wherein C is1-10Straight-chain or branched alkyl being C1-8Straight or branched chain alkyl.
3. A compound of formula I according to claim 1, or a pharmaceutically acceptable salt thereof, wherein C is1-10Straight-chain or branched alkyl being C1-6Straight or branched chain alkyl.
4. A compound of formula I according to claim 1, or a pharmaceutically acceptable salt thereof, wherein R1Is 1- (2-methyl) octyl.
5. A compound of formula I according to claim 1, or a pharmaceutically acceptable salt thereof, wherein C is1-10Straight-chain or branched alkoxy being C1-8Straight or branched alkoxy.
6. A compound of formula I according to claim 1, or a pharmaceutically acceptable salt thereof, wherein C is1-10Straight-chain or branched alkoxy being C1-6Straight or branched alkoxy.
7. A compound of formula I according to claim 1, or a pharmaceutically acceptable salt thereof, wherein C is2-8Saturated aliphatic acyloxy of straight or branched chain being C2-6Straight or branched chain saturated fatty acyloxy.
8. A compound of formula I according to claim 1, or a pharmaceutically acceptable salt thereof, wherein the aromatic acyloxy group is benzoyloxy.
9. A compound of formula I according to claim 1, or a pharmaceutically acceptable salt thereof, wherein halogen is fluorine, chlorine, bromine or iodine.
10. A compound of formula I according to any one of claims 1 to 9, or a pharmaceutically acceptable salt thereof,
wherein,
R1represents 1- (2-methyl) octyl;
R2and R3Each independently represents hydrogen, hydroxy, methoxy, ethoxy, acetoxy, galloyloxy, tribenzylgalloyloxy, benzoyloxy, p-nitrobenzoyloxy, p-chlorobenzoyloxy, or p-fluorobenzoyloxy.
11. The Penicillium purpurogenum BD-1-3(Penicillium purpurogenum BD-1-3) has a preservation number of CGMCC No.4284, a preservation date of 11 months and 1 day 2010 and a preservation place of CGMCC (CGMCC).
12. The Penicillium purpurogenum3-f-31 (Penicillium purpurogenum3-f-31) has a preservation number of CGMCC No.7286, a preservation date of 2013, 3 and 7 days, and a preservation place of CGMCC (China general microbiological culture Collection center) (CGMCC).
13. A process for the preparation of compound 1 and/or 2 comprising the steps of:
1) carrying out fermentation culture on the penicillium purpurogenum of claim 11 or claim 12 to obtain a fermentation broth;
2) filtering the fermentation liquor to obtain filtrate and thalli;
3) extracting the filtrate obtained in the step 2) with ethyl acetate to obtain an ethyl acetate extract of the filtrate;
4) suspending the thalli obtained in the step 2) in acetone aqueous solution with the volume ratio of 50-95%, crushing thalli cells, leaching and filtering, concentrating the filtrate under reduced pressure until the filtrate does not contain acetone, and extracting with ethyl acetate to obtain an ethyl acetate extract;
5) combining the ethyl acetate extracts obtained in the steps 3) and 4), and concentrating under reduced pressure to dryness to obtain an ethyl acetate total extract;
6) directly dissolving the ethyl acetate total extract by using a mixed solvent with the chloroform-methanol volume ratio of 1:1, or dissolving the ethyl acetate total extract by using a large amount of methanol to remove methanol insoluble substances, dissolving the obtained methanol soluble part by using a mixed solvent with the dichloromethane-methanol volume ratio of 1:2, separating by using a 100-mesh silica gel column, performing reduced pressure gradient elution by using a petroleum ether-chloroform-methanol solvent system or a petroleum ether-dichloromethane-acetone-methanol solvent system as an eluent to obtain a crude component containing the compound, and performing two times of SephadexLH-20 column chromatography separation on the obtained crude component, or performing one time of SephadexLH-20 column chromatography and one time of reversed phase silica gel ODS column chromatography separation to obtain a column chromatography component containing the compound as a main component;
7) separating and refining column chromatography components containing the compound by two reverse phase HPLC (high performance liquid chromatography) or separating and purifying by one HPLC to obtain the compound;
wherein, in the two times of SephadexLH-20 column chromatography in the step 6), ethanol with volume fraction of 95% is used for elution for the first time, and a mixed solvent with chloroform-methanol volume ratio of 1:1 is used for elution for the second time;
eluting with ethanol with volume fraction of 95% in the primary SephadexLH-20 column chromatography in the step 6);
performing gradient elution by using a water-methanol-acetone solvent system in the one-time reversed-phase silica gel ODS column chromatography separation in the step 6);
separating and refining twice by using a C-18 column in the step 7) through reversed-phase HPLC, eluting with methanol-water volume fraction of 80:20 for the first time, and eluting with methanol-water volume fraction of 86:14 or 82:18 for the second time;
c-18 column is selected for one-time HPLC separation and purification in the step 7), and methanol-water volume fraction of 81:19 is used for elution;
wherein said compound 1 is a compound of formula I according to claim 1, wherein R11- (2-methyl) octyl, R2=OH,R3H; wherein said compound 2 is a compound of formula I according to claim 1, wherein R11- (2-methyl) octyl, R2=R3=OH。
14. A process for the preparation of a derivative of compound 1 or2 comprising the steps of:
1) dissolving the compound 1 or2 with acetone or anhydrous pyridine;
2) respectively carrying out derivatization reaction with methyl iodide, diethyl sulfate, acetic anhydride, gallic acid, tribenzyl galloyl chloride, benzoyl chloride, p-nitrobenzoyl chloride, p-chlorobenzoyl chloride or p-fluorobenzoyl chloride for 1-48 h or 3-10 days under the conditions of keeping out of the sun at room temperature or keeping out of the sun at 30-80 ℃ and adding hydrochloric acid for catalysis or not adding hydrochloric acid for catalysis;
3) separating and purifying the reaction product by silica gel thin layer chromatography to obtain the compound; wherein said compound 1 is a compound of formula I according to claim 1, wherein R11- (2-methyl) octyl, R2=OH,R3H; wherein said compound 2 is a compound of formula I according to claim 1, wherein R11- (2-methyl) octyl, R2=R3=OH。
15. The preparation method of claim 14, wherein the preparative silica gel plate thin layer chromatography in step 3) employs a mixed solvent of chloroform-methanol in a volume ratio of 80:20 to 99:1 as a developing solvent.
16. A composition comprising a compound of formula I according to any one of claims 1 to 10, or a pharmaceutically acceptable salt thereof, optionally together with one or more pharmaceutically acceptable carriers or excipients.
17. Use of a compound of formula I according to any one of claims 1 to 10 or a pharmaceutically acceptable salt thereof or a composition according to claim 16 for the preparation of a cytoskeletal protein inhibitor, an apoptosis-inducing agent, an inhibitor of tumor cell proliferation, or a tumor cell killing agent.
18. The use of claim 17, wherein the tumor cell is a leukemia cell or an epithelial-derived cancer cell.
19. The use according to claim 18, wherein the epithelial-derived cancer cells are selected from cervical cancer cells, gastric cancer cells, breast cancer cells, lung cancer cells, liver cancer cells, or colon cancer cells.
20. The use of claim 18, wherein the leukemia cells are chronic myelogenous leukemia cells or acute promyelocytic leukemia cells.
21. The use according to any one of claims 17-20, wherein the tumor cells are human chronic myelogenous leukemia K562 cells, human acute promyelocytic leukemia HL-60 cells, human cervical cancer HeLa cells, human gastric cancer BGC-823 cells, or human breast cancer MCF-7 cells.
22. Use of a compound of formula I according to any one of claims 1 to 10 or a pharmaceutically acceptable salt thereof or a composition according to claim 16 for the preparation of a medicament or agent for killing or inhibiting proliferation of tumor cells.
23. The use of claim 22, wherein the tumor cell is a leukemia cell or an epithelial-derived cancer cell.
24. The use of claim 23, wherein the epithelial-derived cancer cell is selected from a cervical cancer cell, a gastric cancer cell, a breast cancer cell, a lung cancer cell, a liver cancer cell, or a colon cancer cell.
25. The use of claim 23, wherein the leukemia cells are chronic myelogenous leukemia cells or acute promyelocytic leukemia cells.
26. The use according to any one of claims 22-25, wherein the tumor cells are human chronic myelogenous leukemia K562 cells, human acute promyelocytic leukemia HL-60 cells, human cervical cancer HeLa cells, human gastric cancer BGC-823 cells, or human breast cancer MCF-7 cells.
27. A method for killing tumor cells or inhibiting tumor cell proliferation in vitro for non-therapeutic purposes comprising the step of administering an effective amount of a compound of formula I or a pharmaceutically acceptable salt thereof according to any one of claims 1 to 10, or a composition according to claim 16.
28. The method of claim 27, wherein the tumor cell is a leukemia cell or an epithelial-derived cancer cell.
29. The method of claim 28, wherein the epithelial-derived cancer cell is selected from a cervical cancer cell, a gastric cancer cell, a breast cancer cell, a lung cancer cell, a liver cancer cell, or a colon cancer cell.
30. The method of claim 28, wherein the leukemia cell is a chronic myelogenous leukemia cell or an acute promyelocytic leukemia cell.
31. The method of any one of claims 27-30, wherein the tumor cells are human chronic myelogenous leukemia K562 cells, human acute promyelocytic leukemia HL-60 cells, human cervical cancer HeLa cells, human gastric cancer BGC-823 cells, or human breast cancer MCF-7 cells.
32. Use of a compound of formula I, or a pharmaceutically acceptable salt thereof, as claimed in any one of claims 1-10, or a composition as claimed in claim 16, in the manufacture of an anti-neoplastic medicament.
33. The use according to claim 32, wherein the tumour is a leukaemia or an epithelial-derived carcinoma.
34. The use according to claim 33, wherein said carcinoma derived from the epithelium is selected from cervical carcinoma, gastric carcinoma, breast carcinoma, lung carcinoma, liver carcinoma, or colon carcinoma.
35. The use according to claim 33, wherein the leukemia is chronic myelogenous leukemia, acute promyelocytic leukemia.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201310191384.5A CN103242348B (en) | 2013-05-22 | 2013-05-22 | Indoline diketopiperazines spirocyclic compound and its production and use |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201310191384.5A CN103242348B (en) | 2013-05-22 | 2013-05-22 | Indoline diketopiperazines spirocyclic compound and its production and use |
Publications (2)
Publication Number | Publication Date |
---|---|
CN103242348A CN103242348A (en) | 2013-08-14 |
CN103242348B true CN103242348B (en) | 2016-01-06 |
Family
ID=48922252
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201310191384.5A Expired - Fee Related CN103242348B (en) | 2013-05-22 | 2013-05-22 | Indoline diketopiperazines spirocyclic compound and its production and use |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN103242348B (en) |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN115215902A (en) * | 2021-04-21 | 2022-10-21 | 中国科学院成都生物研究所 | Water-soluble red edible fungus pigment with anti-inflammatory activity and preparation method and application thereof |
CN116514827A (en) * | 2023-06-26 | 2023-08-01 | 成都中医药大学 | Spiropyrazoline compound, preparation method, application and antitumor drug thereof |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1994018190A1 (en) * | 1993-02-08 | 1994-08-18 | Taisho Pharmaceutical Co., Ltd. | Depsidone compound |
WO2006028263A1 (en) * | 2004-09-10 | 2006-03-16 | Canon Kabushiki Kaisha | Erasable ink, method of erasing image including the same, and method of recycling recording medium using the erasing method |
CN102020649A (en) * | 2010-11-26 | 2011-04-20 | 中国人民解放军军事医学科学院毒物药物研究所 | Diketopiperazine compound as well as composition, preparation method and application thereof |
CN102337220A (en) * | 2011-08-30 | 2012-02-01 | 东华大学 | Penicillium purpurogenum DB1 strain and preparation and application thereof |
-
2013
- 2013-05-22 CN CN201310191384.5A patent/CN103242348B/en not_active Expired - Fee Related
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1994018190A1 (en) * | 1993-02-08 | 1994-08-18 | Taisho Pharmaceutical Co., Ltd. | Depsidone compound |
WO2006028263A1 (en) * | 2004-09-10 | 2006-03-16 | Canon Kabushiki Kaisha | Erasable ink, method of erasing image including the same, and method of recycling recording medium using the erasing method |
CN102020649A (en) * | 2010-11-26 | 2011-04-20 | 中国人民解放军军事医学科学院毒物药物研究所 | Diketopiperazine compound as well as composition, preparation method and application thereof |
CN102337220A (en) * | 2011-08-30 | 2012-02-01 | 东华大学 | Penicillium purpurogenum DB1 strain and preparation and application thereof |
Non-Patent Citations (1)
Title |
---|
产紫青霉G59的两株突变新产抗肿瘤活性产物研究;吴长景等;《国际药学研究杂志》;20100430;第37卷(第2期);第122-126页 * |
Also Published As
Publication number | Publication date |
---|---|
CN103242348A (en) | 2013-08-14 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US20190322638A1 (en) | Dipyridyl alkaloid, preparation method therefor and use thereof | |
CN108640968B (en) | Mixed-source terpenoid and application thereof in preparation of anti-inflammatory drugs | |
CN103992333B (en) | Chromone dimer derivate and its production and use | |
CN107298670B (en) | Application of medicine derived from penicillium oxalicum seclenum ketonic acid H in preparation of anti-human oral epidermoid carcinoma medicines | |
WO1998024926A1 (en) | Gliotoxin derivatives and anticancer agent comprising the same | |
CN103242348B (en) | Indoline diketopiperazines spirocyclic compound and its production and use | |
CN102020649B (en) | Diketopiperazine compound as well as composition, preparation method and application thereof | |
CN103467479B (en) | Spiro-compound, its compositions, Preparation Method And The Use | |
CN109180632B (en) | A method for preparing compound separated from radix Tripterygii Wilfordii | |
CN110812479A (en) | Gallic acid and EGFR target antibody composition and application thereof in lung cancer | |
CN110934877A (en) | Perergosterol and EGFR target antibody composition and application thereof in head and neck squamous cell carcinoma | |
CN102618448B (en) | Drimane-type sesquialter terpene cyclohexenone derivative, preparation method thereof and application | |
CN110903269B (en) | Cadinane sesquiterpene compound and preparation method thereof | |
CN110959851A (en) | Application of agaricus bisporus gallic acid in functional food | |
CN115894467B (en) | Dicyclo-diisopentenyl substituted aspulvinone compound and preparation method and application thereof | |
CN115894408B (en) | Triprenyl substituted aspulvinone compounds, and preparation method and application thereof | |
CN114656393B (en) | Pyrrole-2-aldehyde compound and preparation method and application thereof | |
CN114262270B (en) | Aryl dihydronaphthalene lignans compound and preparation method and application thereof | |
CN109867644B (en) | Benzoquinone compound, preparation method thereof and application thereof in preparation of antitumor drugs | |
CN102174075B (en) | Lipopeptide compound as well as compositions, preparation method and application thereof | |
CN117567438A (en) | Preparation method and application of novel alkaloid aplysingoniopora A | |
CN116621911A (en) | Separation method of isosteroid alkaloid Min Bei Sujia in fritillaria thunbergii and application of anti-Alzheimer disease drug | |
CN115991687A (en) | Diisopentenyl substituted aspulvinone compound and preparation method and application thereof | |
CN104086522B (en) | A kind of spiro-dinaphthyl compound and preparation method thereof | |
CN100582110C (en) | Cyclohexanone analog saturated triring(bridge)compound and its preparation method and uses |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20160106 Termination date: 20170522 |
|
CF01 | Termination of patent right due to non-payment of annual fee |